

Index

Bold page numbers indicate illustrations, *italic* page numbers indicate tables/boxes

- 1p32 abnormalities, 176
 2-CdA, cellular drug resistance, 258, 266
³²P therapy, 468
 3q abnormalities, 408
 3q21.3 abnormalities, 155
 3q26.2 abnormalities, 155
 4q12 abnormalities, 157
 5q33.1 abnormalities, 157
 8p12 abnormalities, 158
 9p abnormalities, 142
 9p21.3 abnormalities, 182
 9q abnormalities, 156
 in T-ALL, 147
 11p15 abnormalities, 156
 11q23 abnormalities, 142, 143, 153–154, 172, 210–214
 AML with, 401
 12p abnormalities, 142, 156
 14q11.2 abnormalities in T-ALL, 147
 15q22 abnormalities, 215
 17p abnormalities, 157
 17q1221 abnormalities, 215
 20q abnormalities, 157
 21q22 abnormalities, 157
- ABL1* gene
 activation, 170
 in CML, 248
 in T-ALL, 147
- ABL1* tyrosine kinase activity, 170
- absolute neutrophil count, 781
 G-CSF therapy and, 806
 parent/patient calculation, 842
- accelerated phase of CML, 11
- access to care
 barriers to, 554–555
 family income and, 551
 lack of, distortion of statistics by, 550, 551
 measures to improve, 554
- acetaminophen, 816
- acid phosphatase stain, 24
- acquired immunodeficiency syndrome (AIDS) and risk of Burkitt lymphoma/leukemia, 386
- activity, physical, 844
- acute bilineal leukemia, 32, 36, 37, 94, 96, 97
- acute biphenotypic leukemia, 32, 36
- acute erythroblastic leukemia, 27, 91
- acute erythroid leukemia, subtypes, 91
- acute kidney injury, 666
- acute leukemia, 100
 of ambiguous lineage, 36–37
 bilineal, 32, 36, 37, 97
 blood transfusion, 5
 CD45 and, 81
 chemotherapy, early attempts, 6
 classification, 21, 23, 28–39, 96
 CD markers, 72, 73
 future trends, 38–39
 diagnosis, 23
 future trends, 38–39
 diagnosis and classification, MPO in, 83
 Down syndrome and, 93
 expression profiles, 82
 flow cytometry, 81
 genetic factors, 51
 and infection, 6
 lineage identification, 80
- neuropsychological consequences, 8
Pneumocystis pneumonia and, 7
 processes mimicking, 98–102
 total care, 7
 undifferentiated, 36, 37
- Acute Leukemia Group B, 8
- acute leukemia of ambiguous lineage (ALAL), 82, 88, 94, 403
 classification, 94
- acute leukemia, mixed phenotype, 88
- acute lymphoblastic leukemia (ALL)
 adolescents and young adults with, 520–525
 array comparative genomic hybridization in, 136
 B-lineage, submicroscopic molecular genetics, 182
BCR-ABL1 fusion in, 140
 cellular drug resistance in, 258, 257–259, 268
 childhood, 8–9
 chromosomal abnormalities, 138, 145, 169, 180
 9p, 142
 numeric, 137–138
 other, 142–144
 structural, 138–140
 targets for PCR, 633
 classification, 28–32
 future trends, 39
 immunophenotypic, 29
 molecular (genetic), 30
 clinical presentation, 334–336
 complications of treatment, 524–525
 continuation treatment, 351–352
 cytogenetics, 142–147
 cytoplasmic granules, 25
 development, 177
 diagnosis, 23
- diagnosis and immunophenotypic classification, 338–340
 diagnostic criteria, 29
 Down syndrome, 504–506
 epigenetics, 239–245
 event-free survival, 367
 genetic classification, 340–342
 genetics of relapse, 184–185
 genome-wide association studies of, 59
 glucocorticoids in, 319
 HSCT in, 532, 533–535
 indications for, 534
 MRD monitoring in, 645
 second transplant, 535
 hyperdiploidy, 51, 137, 340
 in adolescents, 523
 drug responsiveness in, 258, 268
 hypodiploidy, 29, 137, 340, 533
 hypomethylating agents in, 245
 incidence, 431
 age peak, 57
 age-specific, 49
 ethnic and racial differences, 49
 geographic variation, 49
 sex differences, 49
 incidence and distribution, 124
 infant, 353
 initial classification, 2
 intensification and reinduction therapy, 349–350
 L1, 25
 L2, 25
 laboratory findings, 336–338
 methotrexate accumulation in, 310
 molecular genetics, 182–186
 PCR assay, 642
 MRD detection in
 by flow cytometry, 639–640, 646, 645–647

Index

- acute lymphoblastic leukemia
 (*cont.*)
 by PCR, 633, 636, 644,
 642–645
 near-haploidy, 137, 335, 340
 neutropenia prophylaxis, 784
 normal karyotype, 137
 outcome, 185
 as indicator of cancer unit
 success, 552, 556, 557
 pathogenesis and
 pathophysiology, 332–334
 pediatric, cytogenetic
 subtypes, 30
 Ph⁺, 3, 170
 ploidy, 30
 precursor T-cell, 28
 prevalence, 21
 prognosis and outcome by
 subtype, 341
 prognostic factors, 342–344,
 643, 647
 pseudodiploidy, 137
 rates, national, 50
 relapse, 367
 diagnosis of, 367, 643
 HSCT in, 374–375
 immunophenotypes in, 369
 MRD monitoring in, 643,
 645
 new drugs, 375
 prognostic factors, 367–370,
 642, 647
 treatment, 371, 370–376
 remission induction, 349
 monitoring, 643, 645
 risk classification, 344
 risk groups, 342–344
 risk stratification, 185, 369,
 643
 staining, 27
 subtypes, 2, 28
 age at diagnosis and, 520
 classification, 338
 supportive care, 344–345, 349
 as target for treatment in
 developing countries, 552
 T-lineage, submicroscopic
 molecular genetics, 182–184
 total therapy approach,
 344–353
 treatment
 future directions, 354, 525
 monitoring by flow
 cytometry of MRD,
 645–647
 monitoring by MRD PCR,
 642–645
 principles of, 345
 results, 346
 results of St. Jude
 International Outreach
 Program, 556–557
 with aberrant expression of
 myeloid-associated antigens
 (My⁺ ALL), flow cytometry,
 94
 with eosinophilia, 32
 acute megakaryoblastic leukemia
 (AMKL), 27, 34, 401–402
 abdominal abnormalities,
 398
 chromosomal abnormalities,
 154
 diagnosis, 92
 with Down syndrome
 (AMKL-DS), 217, 218–219,
 508–513
 genetic lesions, 220
 immunophenotyping, 92
 molecular genetics, 217–220
 with t(1;22), 219–220
 X-chromosome abnormality
 and, 51
 acute mixed lineage leukemia,
 94, 354
 acute monoblastic leukemia, 26,
 27
 flow cytometry, 81
 staining, 24
 acute monoblastic/monocytic
 leukemia, 34
 acute monoblastic/myelocytic
 leukemia, immunophenotypes,
 90–91
 acute myeloblastic leukemia,
 flow cytometry, 81
 acute myelocytic leukemia with
 maturation, immunophenotype,
 89
 acute myeloid leukemia (AML),
 9–11, 204, 395–412
 anthracyclines in, 316
 array comparative genomic
 hybridization in, 136, 151
 bone marrow transplantation
 in, 535–537
 second transplant, 537
 cellular drug resistance in,
 257, 258, 259, 263, 268
 chromosomal abnormalities,
 targets for PCR, 633
 chromosomal changes,
 148
 numeric, 149–151
 structural, common
 recurrent, 151–154
 structural, uncommon
 recurrent, 154–157
 classification, 32–37, 49,
 147
 future trends, 39
 clinical trial results, 405
 cross-lineage *IG/TCR*
 rearrangements, 125
 cytogenetic abnormalities, 89,
 157–158, 205
 cytogenetically normal AML,
 149, 220–225
 diagnosis, 23
 differential with MDS, 435
 immunophenotyping
 panels, 88
 diagnostic criteria, 29
 Down syndrome and,
 508–513
 dysplastic features and, 23
 epigenetics, 245–248
 familial, CEBP α -dependent,
 296
 gene rearrangements, 124
 genetic lesions, 206
 genetic subtypes, 34–35
 HSCT in, 532, 536
 indications for, 534
 immunophenotype, 88
 incidence, 431
 age-specific, 49
 geographic variation, 49
 initial classification, 2
 leukocyte antigen expression,
 89
 markers, 83, 84
 minimally differentiated,
 staining, 24
 molecular genetics, 204–225
 PCR assay, 647–648
 MRD detection in
 by flow cytometry, 640, 641,
 648–649
 by PCR, 633, 647–648
 neutropenia prophylaxis,
 784
 not otherwise specified, 400
 PCR analysis of junctional
 regions, 636
 prevalence, 21
 prognostic factors, 649
 rates, national, 51
 relapsed, 422, 421–425
 combination therapy in, 315
 after HSCT, 536
 MRD monitoring in, 648
 and related precursor
 neoplasms, 31
 risk assignment, 649
 secondary, 713
 subclassification, 23, 400
 subtypes, 9, 205, 395
 cellular drug resistance in,
 259
 specific therapies for, 412
 staining, 24
 treatment-related, 747–749,
 751–753
 therapy-related, 36
 topoisomerase II
 inhibitor-induced, 153
 treatment, 10–11
 monitoring by flow
 cytometry of MRD,
 648–649
 monitoring by PCR of
 MRD, 647–648
 results of St. Jude
 International Outreach
 Program, 557–559
 treatment-related, 56
 clinical presentation,
 latency, and diagnosis, 749,
 747–749
 cytogenetic and molecular
 aberrations, 738–739
 treatments and outcome,
 751–753
 vs. MDS, 435
 algorithm, 435
 WHO classification, 9, 204
 with aberrant expression of
 lymphoid-associated antigens
 (Ly⁺ AML)
 flow cytometry, 95
 with associated eosinophilia,
 chromosomal abnormalities,
 157–158
 with granulocytic
 differentiation, 26
 with granulocytic sarcoma,
 chromosomal abnormalities
 in, 151
 with inv(16), 35, 400
 with maturation, 33
 with minimal differentiation,
 403–404
 diagnostic criteria, 93
 immunophenotyping,
 92–93
 with minimal granulocytic
 differentiation, 25
 with monosomy, FISH, 150
 with multilineage dysplasia, 33
 with myelodysplasia-related
 changes, 35, 88
 with predominant erythroid
 differentiation, 27
 with recurrent genetic
 abnormalities, 88
 with t(8;21), 34, 398, 400
 without maturation, 33
 immunophenotype, 88
 acute myeloid leukemia with
 minimal evidence of myeloid
 differentiation (AML M0), 33
 acute myeloid leukemia with
 predominant erythroid
 differentiation (AML M6), 34
 acute myelomonoblastic
 leukemia, 663
 acute myelomonocytic leukemia,
 26, 33
 flow cytometry, 81
 immunophenotypes, 90
 acute promyelocytic leukemia
 (APL), 10, 33, 215–217, 402–403
 ATRA in, 317–318

- characteristics, 23
 chromosomal abnormalities, 152–153
 coagulopathy in, 672
 hypergranular, 23, 26, 33
 immunophenotypes, 89–90
 microgranular, 23, 26, 33, 90
 MRD monitoring in, 647
PML-RARA fusion, 33, 648
 with *PML-RARA* fusion, 89
 relapse in, 422, 424, 648
 therapy-related, 36
 treatment, 407–408
 urgency of diagnosis, 152
 WHO classification, 399
- acute undifferentiated leukemia (AUL), 88, 94
 immunophenotyping, 95–96
- acute, use of term, 21
- acyclovir, 775, 777
 development, 7
- adeno-associated vectors, 594, 595, 596–597
- adenoviral vectors, 595–596
- adenovirus, 594
- adjuvant immune therapy, 783–784
- adolescents, ALL treatment, 520–525
- adrenal corticosteroids, lympholytic effects, 4
- adrenal insufficiency, 661
- adrenocortical insufficiency, 687
- adult T-cell leukemia/lymphoma, 100
 immunophenotype, 100
- Advisory Committee on Immunization Practices (ACIP), 7
- AF4/MLL* fusion transcript, 31
- affluence
 and infection, 57
 pediatric cancer survival and, 551
- age
 at diagnosis
 complications and, 662
 secondary cancers and, 730
 treatment of ALL and, 520–525
 maternal, and childhood cancer, 55
 at treatment, neurocognitive issues and, 824
- airway compression, 661, 670, 671
- alcohol, maternal consumption in pregnancy, 55, 56
- alemtuzumab, 477, 563, 564, 572, 623
 side effects, 573
- aleukemic leukemia, 2
- algorithm
 diagnostic, in AML
 abnormal promyelocytes, 32
 blast cells, 32
 erythroid precursors, 32
 FAB classification of AML, 32
 management of treatment-related leukemia, 750
 WHO, for classification of AML, 33
- alkaline phosphatase, 80
- alkylating agents, 725
 in Burkitt leukemia, 3
 and chromosomal abnormalities, 56
 cytogenetic and molecular genetic changes due to, 736–739
 dentofacial effects, 708
 early, 4
 hypersensitivity to, 278, 279
 in therapy-related AML, 36
 infertility and, 705
 new, 622–623
 -related AML/MDS, 404
 -related leukemias, clinical presentation, 748
 resistance to, 258
 secondary cancers and, 725–726, 732
 treatment-related leukemia and, 726
- allergy
 to asparaginase, 318
 uric acid levels and, 388
- alloantigens, 584
- allopurinol, 667
 introduction of, 6
 xanthine nephropathy and, 666
 xanthine oxidase and, 665
- all-*trans*-retinoic acid (ATRA), 90, 215
 in APL, 10–11, 152, 407, 672
 first use, 215
 pharmacodynamics, kinetics, and genetics, 316–318
 plasma concentration, 317
 in relapsed disease, 424
- alpha-naphthyl acetate esterase (ANA), 24
 applications, 27
- alpha-naphthyl butyrate esterase (ANB), 24, 24, 27
- applications, 27
- amegakaryocytic thrombocytopenia, myeloid neoplasia and, 431
- aminopterin, trials of, 4
- AMKL *see* acute megakaryoblastic leukemia
- AML *see* acute myeloid leukemia
- AML genes,
 in FPD/AML, 294
see also CBF genes, RUNX genes
- AML1* gene, 205
 in ALL, 340
 trisomy 21 and, 509
- AML1*(*RUNX1*) gene
 in ALL, 138
 in AML, 148, 150, 151, 157
 amplification in ALL, 144
 fusions, 155
- AML1-CBFA2T3* fusion, 157
- AML1-ETO* fusion transcript, 151–152, 648
- amphotericin B, 6, 782, 783
- anagrelide, 467, 471
- analgesics, 815–818
 procedural, 819
- anaplastic large cell lymphoma, 102
 leukemic phase, 101–102
 immunophenotype, 102
- anaplastic lymphoma kinase (ALK), 102
- anemia, 23
 in ALL, 337, 344
 erythropoietin in, 807
 in JMML, 38
 in primary myelofibrosis, 473
 transfusion in, 794
- anergy, 583, 588
- anthracenedione, 10
- anthracyclines, 10, 265
 in ALL-DS, 506
 in AML, 423
 in AML-DS, 510
 in APL, 407
 cardiotoxicity of, 707–708
 cellular drug resistance, 268
 mechanisms, 264–265
 liposomal, 620
 MoAb conjugates with, 568
 new formulations, 621
 pharmacodynamics, kinetics, and genetics, 316
 in reinduction therapy
 in AML, 423
 in relapsed ALL, 370
- in remission induction therapy in ALL, 348
 resistance to, 258
 secondary AML and, 56
 treatment-related leukemia and, 726
- antiangiogenic drugs in AML, 425
- anti-aspergillus azoles, 6
- antibiotics, 6
 in ALL, 344
 in AML, 10, 411
 in APL, 407
 for bloodstream infections, 773
 in fever and neutropenia, 779, 780–781
 guidelines, 782
 prophylactic, 785
 in typhlitis, 681
- antibodies, monoclonal, *see* monoclonal antibodies
- antibody engineering, of MoAbs, 573
- antibody screening panels, 80
 in ALL, 338
- antibody-dependent cell-mediated cytotoxicity, 563, 565
- anti-CD20 antibody, rituximab, 390
- anticoagulation, 678
 for occluded catheters, 803
- anticonvulsants, 817
 chemotherapy and, 320
- antidepressants, tricyclic, 818
- antiemetics, 829–830
- antifols, trials of, 4
- antifungals, 6, 783
 prophylactic, 785–786
- antigen-specific variable domains, 113
- antigen specificity, 113, 115
- antigen targets for MoAb-based agents, 566
- antigen-induced somatic hypermutations, 116
- antigen-presenting cells, 582
- antigens
 presentation, 582
 recognition by immune system, 113
 targets of immunotherapy, 583–584
- antigen-specific cytotoxic T-lymphocytes, transfer, 586–587

Index

- anti-leukemic drugs, 8
 emergence, 6
- antipyretics, in neutropenia, 815
- antiviral prophylaxis, 785
- anxiety, 830
 procedural, interventions for, 828–829
- APL *see* acute promyelocytic leukemia
- aplastic anemia, 434
 risk of MDS and, 432
- aplastic bone marrow, 99
- apoptosis
 anthracyclines and, 264
 arsenic trioxide and, 11
 B-cell, 76, 76, 77
 drugs targeting, 627
 E2A-HLF and, 172
 E2A-PBX1 and, 172
 epigenetics and, 249
 granulocyte, 78
 leukemic blasts in precursor B-ALL, 30
 new drugs related to, 375
 p53-induced, 385
 PML and, 215
 RAS and, 450
 in severe congenital neutropenia, 297
 suicide gene therapy, 604
 T-cell, 77
 downregulated, 604
 telomere shortening and, 293
 TP53-mediated, 731
- aprepitant, 830
- AraC 266 *see* cytarabine
- ara-CTP
 (1- β -D-arabinofuranoxyl cytosine-5'-triphosphate), 313–315
- ARID genes
 and risk of ALL, 185, 333
 as susceptibility allele, 298
 polymorphisms, 60, 60, 298, 321
- array comparative genomic hybridization, 136
 in ALL, 177
 in AML, 151, 204
- arrhythmias,
 anthracycline-induced, 316
- arsenic trioxide, 3, 10
 in APL, 217, 672
 in relapsed APL, 424
- arsenicals, 3
- asparaginase, 8, 9, 262
 action, 262
 in ALL, 345–348, 349, 521
- anticoagulation and, 678
 cellular drug resistance, 262, 268
 mechanisms, 262–263
 drug–drug interactions, 319
 hyperglycemia and, 686
 in reinduction therapy
 in relapsed ALL, 370
 mechanisms, 318
 new formulations, 620, 621
 pancreatitis and, 682
 pharmacodynamics, kinetics, and genetics, 318–319
 resistance to, 258
 MLL rearrangements and, 257
 prognosis and, 257
 single-dose, 263
 thrombosis and, 679
 treatment in ALL, 340
- asparagine rescue, 263
- aspergillosis, 774, 782–783
- aspirin, 469, 471
- assays
 donor screening, 801
 drug cytotoxicity, *see* cytotoxicity
 cytotoxicity
 ELISA for fungal infection, 783
 low-cost, 552
 MRD, 410, 422
- Association of Pediatric Hematologists/Oncologists of Central America (AHOPCA), 557
- ataxia-telangiectasia, 51, 281–283, 336
 aberrant TCR rearrangement in, 125
 and B-ALL, 336
 complications and, 663
 heritable predisposition, 277
 and risk of Burkitt lymphoma/leukemia, 386
- ATM gene, 281, 283
- ATM protein, 281–282
- ATM–MRN DNA repair pathway, 282
- atomic bomb, leukemia incidence after, 53
- ATRA *see* all-*trans*-retinoic acid
- attention-deficit interventions, 827–828
- Auer rods, 23
 in AML, 26, 33, 34
 in APL, 33, 402
 myeloblasts, 23
 MDS, 37
 staining, 24
- autoimmune disease in JMML, 452
- autoimmune lymphoproliferative disorder, 98
- avascular necrosis of bone in adolescent ALL, 520
- avidin–biotin–HRP complex, 82
- azacytidine, 246–247, 620, 625
 in combination therapy, 248
- azole antifungals, 6, 686
- B-cell acute lymphoblastic leukemia (B-ALL), 122, 383–390
 cellular drug resistance in, 258
 chromosomal abnormalities, 144–146
 chromosomal rearrangements, 169–172, 174
 TCF3-HLF, 172
 clinical features, 338
 diagnosis, 82
 expression profiles, 85
 FISH, 141
 gene rearrangements, 123, 124, 124
 genetic lesions, 206
 IG rearrangements, 173–174
 IG/TCR rearrangements in, 123–124
 MLL rearrangements, 173
 immunologic classification, 376, 127
- B-cell precursor ALL
 compared with T-cell ALL, 339
 genetic subgroups, 342
- B-cell receptors, 75, 76
 antigen specificity, 113
- B-lineage lymphoid malignancies, incidence and distribution, 124
- B-lineage maturation and differentiation, 72–77
- B-lymphocytes
 IG rearrangements, 116, 117
 in JMML, 449
 immunoglobulins on, 113
 maturation, 76
 flow cytometry studies, 99
 normal, 75
 somatic hypermutations, 116
- bacteremia, 773, 773
 catheter-related, 804
- bacterial contamination in blood transfusions, 801
- Barnes, DW, total body irradiation, 7
- barriers to treatment in developing countries, 552, 554–555
- basophilia, 23
- B-cells *see* B-lymphocytes
- BCL2 overexpression, 172
- BCL2 inhibitors, 620
- BCR tyrosine kinase activity, 170
- BCR-ABL1, 460
 activity, 170
 ALL subtypes and, 181
 in CML, 249
 inhibitors, 250
see also Philadelphia chromosome
- BCR-ABL1 fusion gene, 31, 37, 138, 140
 in ALL, 177
 in B-ALL, 170–171
 cellular drug resistance and, 258, 263
 in CML, 248, 460
 diagnosis of CML, 38
 effect on outcome, 171
 in healthy people, 460
see also Philadelphia chromosome
- behavioral changes,
 dexamethasone and, 352
- behavioral issues interventions, 827–828
- bandamustine, 622
- benign bone marrow lymphocytosis, 98
- Bennett, JH, linked leukemia to white blood cells, 1, 11
- benzene, maternal exposure to, 54
- bereavement care, 848
- biclonality, 124
- bilineal leukemia, 354, 403
 acute, 32, 36, 37, 97
- BIM gene, 262
- bio-ballistic “gene gun” technique, 597
- bioflavonoids, MLL and, 56
- biomarker studies, 619
- biomarkers of genetic instability, 61
- biopsy
 bone marrow, 21
 in AML, 399
 dry tap, 92, 473
 immunohistochemistry, 80

- in MDS, 434
 procedure, 22
 specimen preparation, 22
 lung, 776
- biphenotypic leukemia, 36, 94, 354, 403
 acute, 32, 36
 blasts, 96
- birth marks, multiple, childhood leukemia and, 52
- birth order, childhood leukemia and, 55, 57
- birth weight
 childhood leukemia and, 56
 in Fanconi anemia, 278
- bisphosphonates, 479
- BK virus, 779
- blast cells
 in acute leukemia, 21
 in ALL, age at diagnosis and, 520
 in AML, 34, 204, 397
 diagnostic algorithm, 32
 in AML with minimal differentiation, 403
 in AMKL-DS, 218
 L1-type, 28
 L2-type, 28
 levels, diagnosis and, 23
 lineage, 23
 myeloid differentiation in, 33
 proliferation, treatment failure and, 3
 re-accumulation, 3
 in TMD, 507
- blast crisis, 11, 12
 in CML, 461
 lymphoid, 249
 myeloid, 249
- blastic plasmacytoid dendritic cell neoplasms, 37, 88, 97–98
 immunophenotyping, 97
- bleeding
 in ALL, 334
 in APL, 407
 disorders
 FPD/AML, 294
 in APL, 672
 in Noonan syndrome, 288
 therapy-related, in AML, 411
 as early complication, 672
 in essential thrombocythemia, 469
 in polycythemia vera, 464, 465
 platelet count and, 6
 time, 796
- blinatumomab, 568, 620, 623
- BLM actions, 285
- BLM* gene, 285
- blood components, 795
 support, 794–800
- blood evaluation, 2
- blood findings
 chronic GVHD, 540
 in coagulopathy, 672
 at presentation
 in ALL, 336–337
 in AML, 398
 in APL, 403
 in CML, 460
 in essential thrombocythemia, 469
 in JMML, 447, 448
 in MDS, 433
 in polycythemia vera, 465
 in primary myelofibrosis, 473
 in TMD, 507
- blood groups, identification of, 5
- blood transfusions, 5–6
 in ALL, 344
 early use, 3
- blood viscosity, 675
 hyperleukocytosis and, 674
- bloodstream, infections of, 773
- Bloom syndrome, 51, 284–286
 heritable predisposition, 277
- Bodey, GP, neutrophils and infection, 6
- body surface area, drug dosage and, 660, 662
- Boggs, DR, linked neutropenia and infection, 6
- bone
 health, treatment effects on, 9
 lesions
 in AMKL, 402
 in AML, 398
 symptoms and signs in ALL, 334, 337
 in adolescents, 520
- bone marrow
 aspiration, 21
 analgesia, 819, 829
 in diagnosis of ALL, 338
 in diagnosis of AML, 399
 preparing for, 841
 procedure, 21–22
 therapy response analysis, 410
- biopsy, 21
 in AML, 399
 dry tap, 92, 473
 immunohistochemistry, 80
 in MDS, 434
 procedure, 22
 specimen preparation, 22
- blasts, in AML, 33
- CD34⁺ cells, 605
- cellularity
 in acute leukemia, 23
 in refractory cytopenia, 434
- dysplasia, 434
- evaluation, 2
 in severe congenital neutropenia, 297
- failure
 in dyskeratosis congenita, 293
 in Fanconi anemia, 278, 280
 incidence, 431
 in MDS, 431–432
- fibrosis, dry tap aspiration in, 402
- first associated with leukemia, 2
- flow cytometry, 99
- folic acid effect on, 4
- harvest, 532
- in essential thrombocythemia, 470
- in JMML, 448
- in MDS, 433
- in polycythemia vera, 465
- in primary myelofibrosis, 471, 473
- in systemic mastocytosis, 479
- leukemic, 2
- normal hematogones, 98
- relapse
 in ALL, 368
 reinduction therapy, 370–376
- response, 9
- sampling, 21–22
- sites, 22
- transplantation, 7, 530–531
 in AML, 535–537
 in Burkitt lymphoma/leukemia, 390
 in CML, 11
 gonadal function and, 706
 growth after, 702–703
- bone mineral density, therapy and, 709
- bortezomib, 620, 626
- bosutinib, 620, 624
- Boveri, T, work on genetics of cancer, 2
- B-progenitor ALL, gene rearrangements, 174–175
- BRAC1* gene, 731
- Brazil
 AML in, 559
 Burkitt lymphoma/leukemia in, 558
 pediatric cancer management in, 552, 553
 St. Jude International Outreach Program in, 557
- breakpoint fusion genes, as PCR targets, 633–634
- breast cancer-resistance protein (BCRP), cellular drug resistance and, 268
- breast-feeding, 57
- bronchoscopy, 776
- bronchus, compressed, 670
- BTG1*, 261
- Burkitt leukemia, 28, 124
MYC rearrangement in, 173
 therapy for, 3
 see also “mature” B cell ALL
- Burkitt leukemia/lymphoma
 treatment, results of St. Jude International Outreach Program, 557–559
- Burkitt lymphoma, 28, 383–390
 abdominal, CT scan, 387
 endemic vs. sporadic, 386
 endemic, of the jaw, 387
 gene rearrangements, 124
 histology, 384
MYC rearrangement in, 173
- Burkitt lymphoma/leukemia
 endemic, sensitivity to chemotherapy, 558
 in sub-Saharan Africa, 558
- busulfan
 -based myeloablative therapy, 437, 459, 532
 gonadal damage, 706
- cachexia in primary myelofibrosis, 473
- cadherins, in CML, epigenetics and, 250
- calicheamicin, MoAb conjugated, 624
- cancer
 first account, 1
 folic acid and, 4
 genetic basis of, 2, 3
 low priority in developing countries, 550
 predisposition, 276–278
 in ataxia-telangiectasia, 281
 in Bloom syndrome, 285
 in Fanconi anemia, 278
 in neurofibromatosis type 1, 287
 in Nijmegen breakage syndrome, 283
 in Noonan syndrome, 288
 in Shwachman–Diamond syndrome, 291
 programs in developing countries, 552

Index

- cancer (*cont.*)
 risk
 in Diamond–Blackfan anemia, 290
 in dyskeratosis congenita, 293
 secondary
 low thiopurine methyltransferase and, 313
 treatment-related, 723–755
 in under-5 mortality rate, 551
 units, creating, 552
- Cancer and Acute Leukemia Group B, 5
- cancer units, pediatric, establishing in developing countries, 552–556
- cancer, incidence of childhood, geographic variation, 549
- cancer–testis antigens, 583, 583
- candidate gene sequencing
 in B-ALL, 182
 in relapsed ALL, 184
- candidate gene studies, 58–59
 DNA methylation, 245
- candidiasis
 chronic disseminated, 778
 systemic, 774, 782
- carbenicillin, 6
- cardiac monitoring, potassium and, 667
- cardiofaciocutaneous syndrome, 451
- cardiomyopathy, anthracyclines and, 707
- cardiotoxicity, 707–708
 of anthracyclines, 264, 316, 423
 of chemotherapy, 10
 cyclophosphamide, 320
 Down syndrome and, 511
 drug formulation and, 621
- care *see* nursing care, supportive care
- case–control studies, limitations, 61
- caspase 9, 589, 604
 inducible (icasp9), 589, 604
- cataracts, 707
- catheters *see* central venous catheters
- cause-and-effect, between chemotherapy and secondary leukemia, 744
- CBF *see* core-binding factor
- CBF genes, 205
 in FPD/AML, 294
- see also* AML genes, *RUNX* genes
- CBFB-MYH11* fusion, 35, 152, 157, 206, 209, 401
- CBF β –MYH11 fusion protein, 209
- CBL* gene, 455
- CBP(CREBBP)* gene, 156
- CBS* gene, 315, 511
- CD (cluster of differentiation) antigens, 73
- CD1, 73
- CD2, 73, 564, 567
- CD3, 73, 83, 564, 567
- CD3e, 564
- CD4, 73, 564, 567
- CD4⁺/CD8⁺T-cells, 582
 in graft-versus-leukemia effect, 585
- CD5, 73, 564, 567
- CD7, 73, 82, 564, 567
- CD8, 73
- CD9, 73
- CD10, 73, 564
- CD11, 73
- CD11a, 564
- CD13, 73, 83
- CD14, 73, 79
- CD15, 73, 78
- CD16, 73
- CD19, 73, 82, 400, 564, 568
- CD20, 73, 564, 568–569, 604, 623
- CD21, 73
- CD22, 73, 82, 390, 564, 569–570, 623
- CD23, 73, 564, 570
- CD235a, 75–80, 88–93
- CD24, 74
- CD25, 564, 570
- CD30, 74
- CD33, 74, 78, 83, 564, 570–571, 624
 in AML immunotherapy, 425
- CD34, 74, 84
- CD34⁺ cells, 605
- CD36, 74, 79
- CD40, 564, 571
- CD41, 74
- CD42b, 74
- CD45, 74, 80–82, 564, 571
- CD52, 564, 571, 623
- CD56, 74, 400
- CD61, 74
- CD64, 74, 78
- CD65, 74, 79
- CD66, 564, 572
- CD66c, 74
- CD68, 74
- CD74, 564, 572
- CD79, 74, 117
- CD79(a/b), 82
- CD80, 564, 572
- CD83, 74
- CD117, 74, 83
- CD122, 564, 572
- CD123, 75, 564, 572
- CD131, 75
- CD135, 564, 572
 see also FLT3
- CD179, 75
- CD247, 75
- CD261, 564, 572
- CD262, 564, 572
- CD303, 75
- CDKN2* genes, 249
 in ALL, 138, 182
 inactivation, 141
 polymorphisms, 59
 as susceptibility alleles, 298
 in T-ALL, 146
- CEBP* genes, 205, 224–225
 in AML, 149, 408
 in familial AML, 296
 leukemia predisposition and, 294
 mutated, 35
 polymorphisms, 60, 60
 and risk of ALL, 185
 as susceptibility alleles, 298
- CEBPA-dependent familial leukemia
 heritable predisposition, 277
- CEBPB-dependent familial AML, 296
- cell culture, in JMML, 449–450
- cell cycle arrest, 293
- cell death, decreased, treatment failure and, 3
- cell kill assays, 259
- cell lysis
 renal dysfunction and, in Burkitt lymphoma/leukemia, 388
 uric acid levels and, 337
- cell metabolism, drugs to target, 412
- cell cycle progression, inhibitors, 412
- cellular drug resistance, 268
 in ALL, 370
 in AML, 423
 assays, 259
 in CML, 462
 drugs to target, 627
 mechanisms, 259, 462
 anthracyclines, 264–265
 AraC, 266–267
 asparaginase, 262–263
 epipodophyllotoxins, 265–266
 glucocorticoids, 259–262
 methotrexate, 268
 thiopurines, 267–268
 vinca alkaloids, 263–264
 prognostic value, 257
- cellular origins of leukemia, 1
- cellulitis, 774
 perianal, 777
- central airway compression syndrome, 661, 670, 671
- central nervous system (CNS)
 in AML, 399, 407
 infections, 778–779
 leukemia, 31, 337, 350–351, 675–676
 in AML, 399
 on-therapy complications
 in, 682
 relapse, 9, 30, 338, 367
 in AML, 421
 in Burkitt lymphoma/leukemia, 390
 myelopathy in, 684
 treatment, 372–373
 status at diagnosis, 338
 therapy
 in Burkitt lymphoma/leukemia, 389
 sequelae, 706
 tumors, as second cancers, 712
- central venous catheters, 680, 802–803
 complications, 679, 803–804
 infections and, 773
 management algorithm, 680
- centroblasts, 76
- centrocytes, 76
- cerebrospinal fluid (CSF)
 in AML, 399
 analysis, in ALL, 337–338

- in CNS infections, 778
 in relapsed ALL, 367
- Chelyabinsk reactor accident, 53
- chemoprophylaxis, 785–786
see also prophylaxis
- chemotherapy
 in ALL, 342
 in AML, 10
 in Burkitt lymphoma/
 leukemia, 388
 in CNS relapse, 373
 combination, in AML, 411
 dentofacial effects, 708
 developing new agents, 620,
 616–627
 early, 6
 genotoxic, 56
 gonadal damage from, 705,
 709
 growth and, 701
 hepatotoxicity, 681
 hypersensitivity to, 278, 279,
 284, 287
 immunodeficiency and
 infections, 772
 immunosuppression from, 7
 -induced hyperglycemia, 686
 in infants, 662
 in JMML, 457–458
 in MDS, 436
 MoAb-based conjugates, 563
 mucositis and, 679
 neurologic sequelae, 707,
 824–826
 pathophysiology, 826–827
 postremission, 371–372
 in relapsed ALL, new drugs,
 375
 in relapsed AML, 423
 -related distress, 829–830
 responsiveness, 309
 secondary cancers after,
 725–728
 sensitivity to
 in Down syndrome, 511,
 513
 modifying, 598, 604–605
 suboptimal, 310
- Chernobyl reactor accident, 53
- chest radiography findings, in
 ALL, 337
- Childhood Cancer TARGET
 Initiative, 616
- childhood leukemias
 chromosomal abnormalities,
 59
 classification, 49
 epidemiologic studies of, 49
 first case report, 1
 frequencies, 122
 genetic factors, 58–61
 immunogenotype, 122–126
- incidence, 49
 geographic variation, 50
 in USA, 49
 lineage identification, 80
 microsatellite instability and,
 61
 new agents, 620–627
 risk factors
 congenital, 52
 environmental, 52–54
 genetic, 51
 lifestyle, 54–55
 studies of, 49, 51
 risk stratification protocols,
 185
 temporal trends, 50
- Children's Cancer Group, 8
- Children's Cancer Study Group,
 5, 8
- Children's Oncology Group, 5, 8
 genome-wide association
 studies, 60
 risk classification, 345
 studies, 51
- chimeric antigen receptors, 566,
 588, 601–603
- chloroacetate esterase stain, 24,
 27
- chloroma, 34, 37, 398, 663
 intraorbital, 677
- chromatin
 epigenetics, 239
 glucocorticoids resistance and,
 262
 patterns in AML, 225
 regulation, genetic mutations
 and, 246
- chromosomal aberrations
 in APL, 403
 clonal, 135
 in CML, 140
 in MDS, 431–433
 nomenclature, 135
 in PCR assays for MRD, 633
 TCR in T-ALL, 125
- chromosomal abnormalities, 168
 9p, 142
 acute myelomonocytic
 leukemia, 90
 alkylating agents and, 736–739
 in ALL, 138
 numeric, 137–138
 structural, 138–140
 in ALL-DS, 504–505
 in AML, 148, 149, 157–158,
 205, 206, 400
 in ataxia-telangiectasia, 282
 in B-ALL, 144–146, 206
 biphenotypic leukemia, 36
 in Bloom syndrome, 285
 in childhood leukemias, 51
 classification of ALL, 30
- classification of leukemia by, 2
 conventional cytogenetics
 and, 135
 diagnosis by, 9
 immunophenotype-specific,
 144, 145
 in familial AML, 296
 in JMML, 448
 monoblastic leukemias, 91
 in Nijmegen breakage
 syndrome, 284
 in polycythemia vera, 466
 in primary myelofibrosis, 472
 as prognostic factors in ALL,
 342
 in T-ALL, 146–147
 target in PCR analysis, 633
 topoisomerase II poisons and,
 739–744
 treatment-related, 56
- chromosomal fragility
 in Bloom syndrome, 285
 in Fanconi anemia, 279
- chromosomal rearrangements
 in ALL, 169, 180
 AML-specific, 400
 in B-ALL, 170–174
 in DS TMD/AMKL, 508,
 509
 in T-ALL, 176–177
- chromosomal translocations,
 332
- chromosomes
 derivative, 135
 dicentric, 135
 iso-, 135
 marker, 135
- chronic eosinophilic leukemia,
 476
- chronic leukemia
 classification, 21
 diagnosis, 23
- chronic lymphocytic leukemia
 incidence and distribution,
 124
 initial classification, 2
 methylation studies, 245
 prevalence, 21
- chronic lymphoproliferative
 disorders, 23
- chronic myelogenous leukemia
BCR-ABL1 fusion in, 140
 epigenetics, 248–250
 genomic instability in, 249
 incidence, 431
 Ph in, 170
- chronic myeloid leukemia
 (CML), 38, 460–463
 diagnosis, 38
 initial classification, 2
 prevalence, 21
- chronic myelomonocytic
 leukemia and JMML, 38
- chronic myeloproliferative
 neoplasms, leukocytosis in, 23
- chronic phase, 11
- chronic proliferative disorders,
 444–480
- chronic, use of term, 21
- cigarette smoking
 maternal, during pregnancy,
 55, 59
 parental, and childhood
 leukemia, 55, 56
- citrate dextrose, 5
- C-KIT* gene, 205
- cladribine, 621
 drug–drug interactions, 315
- class effect of novel agents, 618
- class switching, ATM and, 282
- clinical course in JMML,
 455–456
- clinical features
 of ALL, 334
 of Burkitt
 lymphoma/leukemia, 387
 of thrombosis, 677
 of TMD, 507
- clinical presentation
 of ALL, 334–336
 of ALL, age at diagnosis and,
 520
 of AML, 397–399
 with minimal
 differentiation, 403
 of CML, 460
 of essential thrombocythemia,
 469
 of JMML, 445–446
 leukostasis syndrome, 674
 MDS, 433
 of polycythemia vera, 464
 of primary myelofibrosis, 472
 of systemic mastocytosis, 478
 of treatment-related leukemias
 and MDS, 747–750
- clinical resistance to AraC, 314
- clinical trials, 8
 in ALL, 346
 AML, results, 405
 erythropoietin, 808
 of G-CSF in ALL, 806
 of gene therapy vectors, 606
 immunotherapy, 584, 584–587
 methodology, 4–5
 of MoAb agents, 566–573, 574
 non-randomized, 5
 patulin, 8
 phase I, 618
 phase II, 618

Index

- clinical trials (*cont.*)
 phase III, 619
 randomized, 5
 Cognitive Remediation Program, 828
 system for new drugs, 617–619
- clofarabine, 375, 423, 620, 621
- clonal eosinophilia, 476
- clonal evolution, 3, 184, 636
 at relapse, 126
- clonal evolution at relapse, 185
- clonal relationship analysis, 126
- clonality
 assessment, 113
IG/TCR rearrangements and, 119–122
 by PCR, 119, 606, 636, 645
 by Southern blotting, 119
 in JMML, 449
 studies
 in ALL, 636, 645
 in essential thrombocythemia, 468
- clones
 predominating, 2
 relapse, 184
- Clostridium difficile*, 777
- CML *see* chronic myeloid leukemia
- cluster of differentiation, 73 *see* CD antigens
- coagulation factors in fresh frozen plasma, 799
- coagulopathies, 661, 672–675
 fresh frozen plasma use in, 799
 on-therapy thrombosis, 677–679
- COBRA assay, 239, 240
- cognitive function, treatment effects on, 9
- Cognitive Remediation Program (CRP), 828
- cognitive-behavioral interventions
 for pain, 819
 during procedures, 829
- collaboration, 8, 9
 in trials, 5
- colony-stimulating factors (CSFs), 784, 805–807
- combination epigenetic therapy, 248, 250
- combination therapy
 AraC and fludarabine, 315
 drug ratio in, 621
 MoAb-based agents in, 574
- combinatorial diversity, 115
- common erythroid–megakaryocytic progenitor (CFU-EM), 79
- Common Toxicity Criteria (CTC), 618
- community education
 in Burkitt lymphoma/leukemia, 558
 non-governmental organization and, 555
- community participation in cancer units in developing countries, 555
- complementarity determining region 3 (CDR3), 116
- complement-dependent cytotoxicity, 563, 565
- compliance
 adolescents and, 845
 non-, indicators, 313
- complications, 660
 in AML, 411
 central venous catheter, 803–804
 in developing countries, 554
 early, 661, 663–677
 disease factors, 660
 leukemia factors, 663
 patient factors, 660–663
 treatment factors, 660, 663
 after HSCT, 537–541
 infectious, 772–786
 late, 701–713
 monitoring for, 846
 neurocognitive deficits, 823–827
 treatment-related leukemia as, 723
 on-therapy, 661, 677–687
 in polycythemia vera, 467
 of stem cell harvesting, 532
 of treatment for ALL, 524–525
- conditioning therapy for HSCT
 neurocognitive effects, 825
 secondary cancers and, 729
- congenital anomalies
 in Fanconi anemia, 278
 non-genetic, childhood leukemia and, 51
 heart defects
 childhood leukemia and, 52
 in Noonan syndrome, 288
- congenital heart defect in Fanconi anemia, 278
- congenital leukemias, 94
- congestive heart failure, anthracycline-induced, 316
- conjugated monoclonal antibodies, 563
- consolidation therapy, 345
 in ALL, 522
- continuation therapy, 9, 345, 845
 in ALL, 351–352
- coping, family, 832
- copy number alterations
 in ALL, 177, 214, 332
 in AML, 206, 214, 397
 diagnosis and relapse, 184
 in T-ALL, 183
- copy-neutral loss-of-heterozygosity, 177
- cord blood, 7
 stem cell transplantation, 375, 530, 531
 in JMML, 459
- core-binding factor (CBF), 207
CBFB-MYH11 fusion and, 152
 in FPD/AML, 295
 leukemias, 152, 206–210, 400, 408
 secondary mutations, 209–210
 transcription complex, 169, 206–208
- corticosteroids
 bone mineralization and, 709
 dose, 319
 for nausea and vomiting, 830
 neurocognitive issues and, 825
 osteonecrosis and, 685
 resistance, 320
see also glucocorticoids
- cost-benefit ratio of therapy, 8
- Costello syndrome, 451
- Côte d'Ivoire, Burkitt lymphoma/leukemia, 389
- cotrimoxazole, 7
- CpG island hypermethylation in JMML, 456
- CpG island methylator phenotype, 239
- Craigie, D, linked leukemia to white blood cells, 1
- cranial irradiation, 350–351
 in AML, 407
 in Burkitt lymphoma/leukemia, 389
 in CNS relapse, 372–373
 CNS tumors and, 712
 dentofacial effects, 708
 growth and, 701, 703, 709
 for intracerebral myeloid tumors, 677
 leukoencephalopathy and, 684
 neurologic sequelae, 706–707, 823–824
 pathophysiology, 826
 thyroid function and, 702
- craniofacial effects of therapy, 708
- craniospinal irradiation
 in CNS relapse, 372–373
 growth and, 701
 thyroid function and, 702
- CREB-binding protein (CREBBP)
 actions, 185
 mutations, 184
- CREBBP gene
 in B-progenitor ALL, 180
 in relapsed ALL, 184, 333
- Creutzfeldt–Jakob disease, blood transfusions and, 802
- CRLF2 gene, 138
 in ALL, 175, 181, 332
 in B-progenitor ALL, 180
 overexpression, 142
 rearrangements, 39
 in B-progenitor ALL, 174–175
 outcome and, 175
- CRLF2, overproduction, 174, 175
- Cryptococcus neoformans*, 778
- cryptosporidiosis, 777
- CT
 chest, 776
 -guided transthoracic needle aspiration, 776
- cultural
 attitudes, treatment of pediatric cancer and, 550, 554, 557
 change, and pediatric cancer unit, 556
 inequality, patterns of, 550–552
- cure, 7
 believed impossible, 9
 first, 3
 by HSCT, 7
 national differences, 9
 rates, 9
 early, 8
 in ALL, 332
 in AML, 10, 408, 411
 in APL, 412
 pediatric cancer, in developing countries, 552
- cutaneous
 infections, 774–775
 lesions in AML, 398
- CXCL12/CXCR4 signaling, 627
- cyclic neutropenia, 297
- cyclin-dependent kinase inhibitors, 182, 620, 626

- encoding genes methylation studies, 240–241
- cyclins, overexpression, genetic abnormalities and, 142
- cyclophosphamide, 8
 in ALL, 521
 in AML, 10
 in Burkitt lymphoma/leukemia, 388, 558
 early use, 4
 gonadal damage, 705, 706
 as myeloablative therapy, 459
 pharmacodynamics, kinetics, and genetics, 320–321
 urinary side effects, 710
- CYP genes, 320
 polymorphisms, 59
- cystitis, 779
- cytarabine (cytosine arabinoside [AraC])
 in ALL, 521
 in AML, 404–406, 423
 in APL, 407
 Burkitt lymphoma/leukemia, 388
 cellular drug resistance, 266, 268
 mechanisms, 266–267
 clinical resistance, 314
 in CML, 461
 in AML-DS, 510, 511
 in hyperleukocytosis, 675
 in infant ALL, 353
 for intracerebral myeloid tumors, 677
 in JMML, 457
 liposomal, 620
 metabolism in AML, 408
 new formulations, 621
 drug–drug interactions, 315, 319
 pharmacodynamics, kinetics, and genetics, 313–315
 resistance to, 258
 sensitivity to
 in ALL, 32, 342
 in AML subtypes, 35
 in TMD, 507
- cytochemical analysis, 22–28
- cytochemical features in diagnosis, 91
- cytochemical staining, 23
 bone marrow, 22
 Burkitt/non-Burkitt lymphoma, 383
- cytochemistry in AML with minimal differentiation, 403
- cytochrome P450, 59, 732–733
- cytogenetic abnormalities alkylating agents and, 736–739
 in AML, 89, 409
 in childhood leukemias, 51
 in “mature” B-ALL, 87
 in infant leukemia, 56
 in pro-B-ALL, 85
 topoisomerase II poisons and, 739–744
- cytogenetic ploidy analysis, 30
- cytogenetics
 alkylating agent-induced changes in, 736–739
 of ALL-DS, 504–505
 of AML, 395
 of AML subgroups, 400
 of APL, 402
 of Burkitt lymphoma/leukemia, 385
 conventional, 135
 in AML, 147, 151
 of AML-DS, 508
 early, 2
 molecular, 135
 in cytogenetically normal AML, 220–225
 nomenclature, 135
 of JMML, 449
 of MDS, 431, 433
 of polycythemia vera, 466
 of primary myelofibrosis, 472
 of treatment-related leukemia, 744
 role in diagnosis of ALL, 185
 studies, in AML, 399
 subsets, event-free survival and, 2
 topoisomerase II poisons-induced changes in, 739–744
 utility, in AML, 151
- cytokine receptor-like factor 2, 174 *see* CRLF2
- cytologic features of myelodysplasia, 433
- cytomegalovirus, transfusion-associated, 800
- cytopenia, 23
 causes, 434
 in Fanconi anemia, 278
 in MDS, 37
 pre-ALL, 99
 refractory, of childhood, 38
- cytoplasmic granules, 25, 28
 ALL blasts, 28
 APL, 33
 lymphoblasts, 23
 monoblasts, 23
 myeloblasts, 23
 promyelocytes, 23
- cytoplasmic vacuoles, 25
 in blast cells in ALL, 28
 in Burkitt leukemia, 28
 lymphoblasts, 23
 monoblasts, 23
- cytoreductive therapy, 471
- cytosine arabinoside, 10 *see* cytarabine (AraC)
- cytotoxicity
 assays, 257, 259
 differential staining of cytotoxicity, 257
 fluorometric microculture cytotoxicity assay (FMCA), 257
 methylthiazol–tetrazolium (MTT)-based, 257
 novel agents, 616
 mechanisms of MoAb-based therapies, 565, 563–566
- dacetuzumab, 564, 571
- daclizumab, 564, 570
- danusertib, 620
- DAPK1, 245
- dasatinib, 12, 250, 462, 620, 624
 activity, 425
- daunorubicin, 10, 265
 cellular drug resistance, 264, 265
 in AML, 404–406
 P-glycoprotein drug resistance and, 423
 pharmacodynamics, kinetics, and genetics, 316
- Dausset, J, HLA typing and matching, 7
- dCK, 314
- dCK, 267
- DDC polymorphisms, 60, 60
- death
 from complications, 660
 leukostasis syndrome and, 673
 in monoblastic leukemia, 675
 preparing for, 847
- decitabine, 247–248, 620, 625
 in combination therapy, 248, 250
 as hypomethylating agent, 246
 trials, 244, 250
- delayed intensification, 9
- deletion, definition, 135
- deletions
 in ALL, 175, 179
 del(5q), 737–738
 del(7q), 736
- demethylating agents, 620
- demographic risk factors, 54
 secondary cancers, 730
- demographics of Fanconi anemia, 278
- denaturing gradient gel electrophoresis, 121
- dendritic cells, 582
 differentiation, 37
 expression profiles, 82
 immunotherapy with, 587
 leukemias, 37
- dental abnormalities, after therapy, 708–709
- depression, 831
- developing countries
 childhood mortality in, 550
 establishing pediatric cancer units, 552–554, 555–556
 pediatric cancer in, 550
 results of treatment in, 556–559
- developmental therapeutics, 616–627
- dexamethasone
 adrenal insufficiency and, 687
 in ALL-DS, 506
 in continuation treatment in ALL, 352
 dose, 319
 drug–drug interactions, 319
 for nausea and vomiting, 830
 neurocognitive issues and, 825
 osteonecrosis and, 524, 685, 710
 pharmacodynamics, kinetics, and genetics, 319–320
 in remission induction therapy in ALL, 348
 in spinal cord edema, 676
- dexrazoxane, 348, 708
 secondary leukemia and, 727
- diabetes insipidus, 661
- diagnosis
 of ALL, 338–340
 of AML, 397–399
 of AML with minimal differentiation, 403
 Burkitt lymphoma/leukemia, 387
 of chronic GVHD, 540
 of CML, 461
 delayed in poor regions, 554
 diagnosis and referral phases of care, 840
 differential
 eosinophilia, 477
 in essential thrombocythemia, 470
 of JMML, 449
 of mastocytosis, 480
 of MDS, 434–435
 in polycythemia vera, 466

Index

- diagnosis (*cont.*)
 in primary myelofibrosis, 473
 fungal infections, 783
 immunophenotyping panel, 338
 JMML, 448
 of hypereosinophilic syndrome, 476
 of mastocytosis, 478
 of myelopathy, 684
 of neurofibromatosis, 455
 of polycythemia vera, 464
 primary myelofibrosis, 473
 pulmonary disease, 776
 in relapsed AML, 421
 of TMD, 507
 of treatment-related leukemias and MDS, 747–750
 urgency of
 in APL, 152
 in myelopathy, 684
- diagnostic criteria
 by FAB category, 29
 in MDS, 434
 for systemic mastocytosis, 478
- dialysis, 669
- Diamond, L, antifolates work, 4
- Diamond–Blackfan anemia, 290–291
 heritable predisposition, 277
 myeloid neoplasia and, 431
- dic(9;20), 141
 in ALL, 141
- diet
 and childhood leukemias, 55
 in hyperglycemia, 686
 maternal in pregnancy, 55
 AML and, 56, 739
 neutropenic, 785
 in pancreatitis, 682
 during remission induction treatment, 349
 during treatment, 841
 in typhlitis, 681
- differential staining of cytotoxicity assay, 257
- differentiation antigens, 583, 583
- differentiation therapy in drug-resistant AML, 424
- DiGuglielmo disease, 91
- diphtheria immunotoxin conjugate, 567
- diploidy, 30
 in ALL, 137
- discharge, distress and, 846
- disease-free survival, 5
- diseases of poverty, 550
 mortality, by country, 551
- under-5 mortality rate and, 550
- disseminated intravascular coagulation, 673
 in AML, 398
 in APL, 407, 411
- distress
 parental, 832, 843
 procedural, interventions for, 828–829
 psychological, 830
- DNA
 copy number alteration
 in ALL, 178
 copy number alteration in ALL, 177
 damage mechanisms, 744–747
 index, 30
 lesions in Fanconi anemia, 278
 methylation
 repair, 278
 in ataxia-telangiectasia, 281
 ATM–MRN pathway, 282
 in Bloom syndrome, 284
 defective, 278
 in Down syndrome, 509
 drugs to target, 627
 gene therapy for, 281
 in Fanconi anemia, 279, 280
 in Nijmegen breakage syndrome, 284
 repair genes, 61
 in family cancer syndrome, 730–732
 polymorphisms, 59, 731
 replication
 errors, 278
 synthesis, ara-CTP and, 313
 vaccines, 600–601
- DNMT gene, 225
 mutations, 246, 249
- Donné, A, observed high white blood cell counts, 1
- donor
 lymphocyte infusion in CML, 463
 lymphocyte infusion, 535, 536, 585
 in JMML, 460
 prophylactic, 585
 matched family donor (MFD), 459
 matched sibling donors (MSDs), 530
 matched unrelated donor (MUD), 459
 mismatched donor, 531, 532
 risk, 532
 screening donors, 531, 800
 assays, 801
 selection, 528–530
 T-cells, unmanipulated, 585
 transplants, 531
- dose-finding studies, 618
 molecularly targeted drugs and, 619
 multiagent regimens, 619
- dose-limiting toxicity, 618
 defining, 619
- dosing
 opioids, 816
 protocols
 secondary cancers and, 729
 treatment-related leukemia and, 727, 728
- DOT1L
 in *MLL* leukemia, 173, 754
 recruitment, 213
- Dounreay (UK), 53
- Down syndrome (DS), 503
 ALL in, 504–506
CRLF2 in, 505
 AMKL with (DS AMKL), 34, 217–220, 508–513
 AML cure rate and, 10
 AraC metabolism in, 314
 -associated B-ALL, *CRLF2* rearrangements in, 174
 complications and, 663
 drug sensitivity in, 511
 incidence of leukemia, 9
JAK mutations, 142
 leukemia risk, 93, 503
 methotrexate and, 352
 methotrexate toxicity in, 310
 MDS and, 38
 myeloid leukemia related to, 34
 myeloid proliferations associated with, 38, 93–94
 and risk of ALL and AML, 150, 503
 risk of leukemia, 51
 t(8;14)(q11.2;q32) in, 146
 transient myeloproliferative disorder of, 34, 506–508
- doxorubicin
 cardiotoxicity, 707
 pharmacodynamics, kinetics, and genetics, 316
- Drosophila*, homology with, 168, 171, 172
MLL, 210
RUNX, 206
- Drug Development Group (DDG), 617
- drug resistance
 corticosteroid, 320
 drugs to target, 412, 627
 genes, therapeutic use, 605
 primary, definition of, 462
- drug–drug interactions, 349
 AraC in, 315
 asparaginase in, 319
- glucocorticoids, 320
 synergistic, in AML, 423
 triazoles, 783
 vincristine, 320
- drugs
 cellular resistance, genetics and, 257–269
 cytotoxicity assays *see* cytotoxicity
 development process, 616–617
 current challenges, 619–620
 effects, host polymorphisms and, 3
 metabolism
 in AML, 408
 genetic variations and, 732
 secondary leukemias and, 732–734
 susceptibility to malignancy and, 397
 molecularly targeted, 624–627
 new formulation and delivery, 621
 novel for childhood leukemia, 620–627
 resistance 8
 in AML, 423
 treatment of relapse and, 370
see also cellular drug resistance
 responsiveness, genetics and, 257–269
 targeting apoptosis, 627
- DS *see* Down syndrome
- duplication, definition, 135
- dyskeratosis congenita, 292–294, 432
 heritable predisposition, 277
 myeloid neoplasia and, 431
- dysplasia
 in AML, 33
 causes, 434
 multilineage, 32
- dysplastic features, diagnosis and, 23
- E2A-FB1* fusion, 140
 in ALL, 138
- E2A-HLF* actions, 172
- E2A-HLF* fusion, 138, 140
- E2A-PBX1* actions, 172
- E2A-PBX1* fusion, 30, 139, 139
- E2A-ZNF384* fusion, 140
- ear, nose, and throat infections, 776
- echinocandins, 6, 783

- education
 community
 non-governmental organizations and, 555
 family, in developing countries, 555
 ongoing in St. Jude International Outreach Program, 556, 557
 parental, in developing countries, 552
 patient and family, 841
 timing, 842
see also training
- educational attainment, after therapy, 826
- Ehrlich, P, introduced histochemical staining, 2, 12
- El Salvador
 AHOPCA-1 protocol, 557
 pediatric cancer management in, 554
 treatment of ALL in, 556–557
 treatment of AML in, 557–559
 treatment of Burkitt leukemia/lymphoma in, 557–559
- El Salvador–Guatemala–Honduras II (SGH-II) study, 556–557
- El Salvador I (ELS-I) protocol, 556–557
- ELANE, 297
- electrolyte balance
 in ALL, 344
 in tumor lysis syndrome, 664
- electromagnetic fields, 54
 and AML, 397
- electroporation, 597, 600
- Elion, G
 work on acyclovir, 7
 work on purines, 4, 6
 work on trimethoprim, 7
- embolization, catheter-associated, 804
- emergency situations
 in Burkitt lymphoma/leukemia, 389
 central airway compression, 670
 fever in neutropenia, 779
 hyponatremic seizures, 686
 monoblastic leukemia with hyperleukocytosis, 675
 pain, 816
 spinal cord compression, 676
- emotional needs, 840
- empathy, role of, 5
- encephalitis, 778
- endocrine abnormalities in Fanconi anemia, 278
- endocrine complications, on-therapy, 685–687
- endocrine deficiency, chronic GVHD and, 539
- endocrine toxicity, late, 701–706
- endpoints, trial
 molecularly targeted drugs and, 619
 Phase II, 618
- enhancer core motif (TGT/cGGT), 206
- enterococcal infections, 6
- environmental risk factors, 52–54
 genetic susceptibility and, 61
- eosinophilia, 23
 ALL with, 32
 bone marrow in AML, 35
 classification, 475
 clonal, 476
 differential diagnosis, 477
- eosinophils, in AML with inv(16), 401
- ephrin family, 242
- epidemiology, 49–61
 AML, 396–397
 Burkitt lymphoma/leukemia, 385
 chronic myeloid leukemia, 460
 essential thrombocythemia, 468–469
 hyperglycemia, 686
 JMML, 445–446
 of leukemia in Down syndrome, 503
 MDS, 430–432
 molecular, 58
 osteonecrosis, 685
 of polycythemia vera, 464
 of primary myelofibrosis, 472
 treatment-related cancers, 724–725
 trends in diagnostic practice and, 49, 50
- epigenetic
 changes in leukemia, 2, 3
 regulation, drugs to target, 412
 therapy, 754
 in CML, 250
 combination, 248
 in JMML, 457
 in myeloid leukemia, 246–248
- epigenetics
 of ALL, 239–245
 in AML, 245–248
 in CML, 248–250
 definition, 239
- genetics and, 246
 glucocorticoid responsiveness and, 262
 of MDS, 245–248
- epipodophyllotoxins, 265
 cellular drug resistance mechanisms, 265–266
 drug–drug interactions, 319
 pharmacodynamics, kinetics, and genetics, 316–317
 secondary AML and, 713
 secondary cancers and, 729, 732
 sensitivity to, in AML subtypes, 35
 therapy-induced leukemia and, 56, 404, 726–727
- epiratuzumab, 569
- Epstein–Barr virus, 386–387
 -associated genes, future therapy and, 390
 blood transfusions and, 802
 lymphoproliferative disorder, 586–587
 HSCT and, 537
- ERG, 219, 510
 deletions, 182
- erythremic myelosis, 91
- erythroblasts, characteristics, 23, 24
- erythrocytosis, in differential diagnosis of polycythemia vera, 466
- erythroid maturation, 79
 and differentiation, 80
- erythroid precursors
 in AML, 34
 diagnostic algorithm, 32
 erythropoietin and, 33
- erythroleukemia, 34, 91
 staining, 24
- erythropoietin, 807
 clinical trials, 808
 levels in erythrocytosis, 466
 in primary myelofibrosis, 474
- esophagitis, 777
- essential thrombocythemia, 468–471
 and AML, 470
 and myelofibrosis, 470
 WHO diagnostic criteria for, 468
- estimated risk of relapse, 9
- ethics of randomization, 5
- ethnic and racial differences
 in ALL, 334, 339, 342
 in essential thrombocythemia, 468
 in incidence of AML, 396
- in leukemic subtypes, 340
 in osteonecrosis, 685
 secondary cancers and, 730
- etiology, 49–61
 infant leukemia, 56–58
 treatment-related leukemia, 744–747
- ETO, 207
- etoposide, 265, 388
 in AML, 404–406
 cellular drug resistance, 265
 drug–drug interactions, 319
 in JMML, 457
 leukemogenicity, 56
 resistance to, 258
 secondary cancers and, 732
 treatment-related leukemia and, 726
- ETS2 protein, 509
- ETV6–RUNX1 fusion, 333
 in ALL, 177, 340
 in B-ALL, 169–170
- ETV6–RUNX1, role in leukemogenesis, 170
- European Medicines Evaluation Agency (EMA), 617
- event-free survival, 5
 in ALL, 367
 adolescents, 523
 age at diagnosis and, 520, 523
 in ALL-DS, 505
 in AML, 149, 153, 204, 410
 in APL, 11, 215
 B-lineage leukemia, 321
 in DS AML, 510
 HSCT and
 in ALL, 533–535
 in AML, 535–536
 improvement in, 9
 in JMML, 456, 459
 methotrexate plasma concentration and, 310
 relapse category and, 369
 in relapsed ALL, 368, 369
 risk group and, in relapsed ALL, 369, 370
 variability, 2
- EVII overexpression, 155
- evolution, leukemia, 11
- exchange transfusion
 in ALL, 344
 in AML, 411
 for hyperleukocytosis, 675
- expansion of T-cells, 585, 588
- expression profiles
 B-ALL, 85
 B-lineage, 72–77
 Burkitt lymphoma, 384
 CD marker, 72

Index

- expression profiles (*cont.*)
 myelocytic and monocytic lineages, 78–79
 T-lineage, 78
- extramedullary
 disease, 34, 676
 hematopoiesis, 467, 472
 tests for, 473
 treatment, 474
 leukemic tumors, 663
 manifestations
 in AML with *inv(16)*, 400
 in relapsed ALL, 367
 myeloid tumors, 398
 relapse, in AML, 421
- extravasation, 804
- FAB *see* French–American–British
- Faces Pain Scale, 814, 815
- facilities, in developing countries, 554
- faggot cells, 402
- familial AML, 397
 CEBP β -dependent, 294–296
- familial MDS, 432
- familial monosomy 7, 51
- familial Noonan syndrome, 454
- familial patterns, 52
- familial platelet disorder (FPD), 294
 heritable predisposition, 277
 with propensity for AML (FDP/AML), 294–295
- familial thrombocytopenia, myeloid neoplasia and, 431
- family
 adjustment, 832, 843, 845
 in relapse, 847
 cancer syndrome gene mutations, 730–731
 education, 552
 in developing countries, 555
 support of, 5
- FANC genes, 279, 280
- FANCD2–FANCI complex, 279, 280
- Fanconi anemia, 51, 278–281
 complications and, 663
 heritable predisposition, 277
 myeloid leukemia in, 430, 431
 myeloid neoplasia and, 431
- Farber, S, 12
 antifols work, 4
 total care, 7
- farnesyltransferase inhibitors, 458, 620, 624
- fatigue, 844
- FBXW7*, 183
- fentanyl, 819
 transdermal, 816
- fetal exposure to drugs, 333
- fetal loss and childhood leukemia, 55
- fever
 in ALL, 334, 344
 in AML, 411
 definition, 779
 management guidelines, 781
 and neutropenia, 779–781
 priority admission for, 842
- FHIT*, 267
- FIP1L1-PDGFR α* fusion, in eosinophilic disorders, 476–477
- FISH *see* fluorescence in situ hybridization
- FLACC pain score, 814, 815
- flavopiridol, 620, 626
- flora, microbiologic, changes in, and infection, 772
- flow cytometry, 2, 9, 80, 639
 acute leukemias, 81, 94–97
 in AML, 32
 anaplastic large cell lymphoma, 102
 assay of MRD, 410
 B-cell maturation, 99
 for detection of relapse in ALL, 368
 in diagnosis
 of ALL, 338
 of AML, 88, 90
 of APL, 89
 DNA index, 30
 future directions, 102
 hepatosplenic T-cell lymphoma, 101
 limitations, 642
 lineage assessment, 23
 in MRD monitoring, 641, 638–642, 646, 645–649
 normal pediatric bone marrow, 80
 permeabilization in, 83
- FLT3* 223, 222–224
 in AMKL, 220
- FLT3* gene, 205, 223
 activating mutations, 223
 in ALL, 138, 142, 173, 332
 in AML, 150, 152, 408–409
 in APL, 152
 duplication, 9
 internal tandem duplications (ITDs), 409
- mutations, 30, 32
 mutation affecting tyrosine kinase domain, 223, 224
- fluconazole, 782
- fludarabine, 423, 437
 drug–drug interactions, 315
 as myeloablative therapy, 459
- fluid
 balance in ALL, 344
 overload, transfusion and, 794
- fluorescence in situ hybridization (FISH), 136
 in AML, 149, 151, 152
 analysis, 139, 141, 150
 interphase, identifies chromosomal changes, 2
MLL and, 153
MLL probe, 154
 pediatric ALL, 30
 role in diagnosis of ALL, 185
 with *TEL-AML1* probe, 144
- fluorometric microculture cytotoxicity assay, 257
- foamyvirus, 594
- folate
 deficiency effects, 4
 depletion
 in Down syndrome, 311
 neurocognitive effects, 827
 effects, 4
 maternal supplementation in pregnancy, 54, 58
 pathway
 genetic polymorphisms, 58, 311
 methotrexate and, 309
- Food and Drug Administration (FDA), 617
- formulations, drug, 619
 new, 621
- forodesine, 375, 622
- foundations *see* non-governmental organizations
- Fowler’s solution, 3
- “FPC” prognostic scoring system in MDS, 436
- FPD *see* familial platelet disorder
- French–American–British (FAB) classification
 ALL, 28–29
 AML, 23, 32, 204
 algorithm, 32
 MDS, 37, 429
- fresh frozen plasma, 799
- Fuller, H, first diagnosis of leukemia, 1, 11
- funding
 for cancer units in developing countries, 555, 556
 for patients, in Brazil, 553
- fungal infections, 6, 775, 781–783
 after HSCT, 537
 ear, nose, and throat, 776
 myeloablative therapy and, 527
 pre-existing, 663
 pulmonary, 775
- gabapentin, 817
- galiximab, 564, 572
- gammaretroviral vectors, 593
- gamma-secretase inhibitors, 183, 620
- ganciclovir, 604
- gastrointestinal complications
 infections, 776–778
 on-therapy, 679–682
 features of JMML, 446
- GATA1*, 93, 205, 218, 512
 in AML, 151
 in DS AMKL, 217, 218, 508, 509, 511
 and trisomy 21, 219
- GATA1* proteins, 218–219, 508, 509, 511
- G-CSE, 805–807
 clinical trials, 806
 in neutrophil recovery, 411
 pre-leukapheresis, 800
 prophylactic, in ALL, 345
 secondary leukemia and, 727
 in severe congenital neutropenia, 297
 therapy, MDS and, 431
- GCSF* gene, 260
- G-CSF receptors, in severe congenital neutropenia, 297
- gemcitabine, 423
- gemtuzumab ozogamicin, 10, 404, 564, 565, 571, 620, 624
 in AML, 412
 in relapsed AML, 425
 side effects, 573
- gender differences in side effects, 824
- gene expression profile
 in AML with minimal differentiation, 403
MLL-rearranged ALL, 173
- gene expression profiling, 136
 in ALL, 39, 734
 in AML, 204
 future trends in diagnosis, 38

- in JMML, 456
 leukemia, 3
MLL PTD, 214
 pediatric ALL, 39
 prognostic implications, 39
- gene marking, 605–606
- gene silencing, 599
- gene therapy
 as cause of leukemia, 606–607
 Epstein–Barr virus genes and, 390
 in Fanconi anemia, 280
 host modification, 601–605
 protocols, 607
 tumor cell modification, 597–601
 vectors, 594, 593–597
- gene transfer, 589, 593–607
- gene, suicide, 589, 604
- genes
 aberrantly expressed, as PCR targets, 634
 breakpoint fusion, as PCR targets, 633–634
 mutations, in family cancer syndrome, 730–731
 rearrangements
 and cellular drug resistance, 257–259
 cross-lineage, 123, 125
 pediatric ALL, 30
 processes, 113–119
 in T-ALL, 145, 146
 in utero, 144, 509
- GeneScan analysis, 121, 122, 123
 sensitivity, 128
- genetic abnormalities
 in advanced CML, 249
 in ALL, risk of relapse and, 342
 in AML, 88, 397, 409
 in AML subtypes, 33, 35, 399
 acquired, 51, 52
 in Burkitt lymphoma/leukemia, 385
 in FDP/AML, 295
 inherited, 51, 52
 leukemia classification by, 30
 in precursor T-ALL, 32
 pro-B-ALL, 85
 submicroscopic molecular genetics in, 136
- genetic abnormalities
 in DS AMKL, 220
 in TMD, 220
- genetic alterations
 in ALL, 180, 181, 182
 in B-progenitor ALL, 170
 and cellular drug resistance, 257–259
 DNA methylation and, 246
- DNA repair errors and, 278
 in JMML, 450–455
 in leukemia, 2, 3
 in leukemic blast cells, 332
 in T-ALL, 170
 secondary, 184
- genetic classification
 of ALL, 30–32
- genetic classification of ALL, 340–342
- genetic instability
 in cancer, 2
 MDS and, 432
- genetic lesions in AML, 397
- genetic mechanisms of heritable predisposition, 277
- genetic predisposition
 in cancer, 276
 to secondary leukemias, 730–735
 for treatment-related leukemia, 730
- genetic susceptibility, 58–61
 environmental risks and, 61
- genetic syndromes, 51
- genetics
 of cancer, early work, 2
 cellular drug resistance and, 257–269
 in CML, 460
 epigenetics and, 246
 of relapse, in ALL, 184–185
 role of in acute leukemias, 52
- genome-wide
 association studies, 60, 59–61
 in ALL, 177
 of susceptibility alleles, 298, 735
 methylation profile study in chronic lymphocytic leukemia, 245
 profiling, 177
 in ALL, 173
 in AML, 204
 in B-ALL, 178
 in relapsed ALL, 184
 in T-ALL, 183
- sequencing
 in ALL, 182
 cytogenetically normal AML, 221
 future trends, 186
- genomic instability, 61
 in CML, 249
- gentamicin, 6
- germline mutations, 276
 in Diamond–Blackfan anemia, 290
 in dyskeratosis congenita, 294
 in familial AML, 296
- in family cancer syndrome, 730
- in FDP/AML, 295
- heritable conditions
 diagnosed by, 279
 in JMML and Noonan syndrome, 446, 450–452, 454, 455
 leukemia predisposition and, 278
 in *NBN*, 284
 in *NF1*, 286, 451
 in RAS–MAPK pathway, 286, 450, 452
- germline polymorphisms in leukemogenesis, 333
- Gloor, W, first cure by, 3
- glucocorticoid receptors, 259, 260
 cellular drug resistance and, 259–261
 complex with glucocorticoid *GCR* genes
- glucocorticoids, 259
 adrenocortical insufficiency and, 687
 bone mineralization and, 709
 cellular drug resistance, 268
 mechanisms, 259–262
 complex with glucocorticoid receptor, 259, 260
 in continuation treatment in ALL, 352
 hyperglycemia and, 686
 neurocognitive effects, 827
 osteonecrosis and, 710
 pharmacodynamics, kinetics, and genetics, 319–320
 in remission induction therapy in ALL, 348
 resistance to, 257, 258, 259, 370
MLL rearrangements and, 257
 thrombosis and, 679
- glutathione *S*-transferases
 anthracyclines and, 265
 oxazaphosphorines and, 320
- glycolysis, glucocorticoid resistance and, 261
- glycosyl phosphatidylinositol, 79
- GM-CSF, 411, 805
 hypersensitivity, in JMML, 449
 in neutrophil recovery, 411
 receptor-targeted therapy, 458
- Goldin, A, multiagent therapy, 8
- gonadal function, 705–706
 after transplant, 706
- graft engineering, ex vivo, 533
- graft-versus-host disease (GVHD), 7
 acute, 538–539
 grading, 539
 CD13 and, 83
 chronic, 539–541
 grading, 540
 in CML, 11
 in Fanconi anemia, 280
 in JMML, 459
 neurocognitive effects, 825
 in relapsed AML, 424
 source of stem cells and, 530–531
 suicide genes in, 604
 transfusions and, 796
- graft-versus-leukemia effect, 412, 425
 AML and, 423
 cellular mechanism, 584
 in JMML, 459
 KIR mismatching and, 529
 reduced-intensity conditioning and, 532
 suicide genes and, 604
- graft-versus-lymphoma effect, 390
- Gram-negative bacteria, 6, 773
 in catheter infections, 804
 in typhlitis, 777
 in urinary tract infections, 779
- Gram-positive bacteria, 6, 773
 resistant, 6
- granular ALL, 28
- granulocyte colony-stimulating factor *see* G-CSF
- granulocyte transfusion, 784, 799
- granulocyte–macrophage colony-stimulating factor *see* GM-CSF
- granulocytes, 78
- granulocytic component in AML, 33, 34
- granulocytic sarcoma, 34, 398
 diagnosis, 28
- grief, 840, 848
- growth
 after therapy, 701–702, 703
 chemotherapy and, 701
 control, *PML* and, 215
 factor, use in HSCT, 605
 failure, 7
 hormone
 cranial irradiation and, 701
 deficiency, after total body irradiation, 703
 methotrexate and, 701
 therapy, 703

Index

- GST polymorphisms, 59, 408
- Guatemala, treatment of ALL in, 556
- guidelines
 for management of febrile neutropenic patients, 779
 for management of patients with persistent fever, 781
 regarding the duration of antibiotic, 782
 supportive care, 541
 for use of blood products, at St. Jude Children's Research Hospital, 802
 for use of high-dose methotrexate, 559
 WHO, on pain therapy, 815
- GVDH *see* graft-versus-host disease
- HAGE, 250
- harvesting
 of bone marrow, 532
 of PBSC, 532
- HAX1, 297
- health
 behaviors, in survivors, 846
 indicators in under-5 mortality rate, 550
 inequality, measures of, 550
 insurance for survivors, 846
 priorities
 in developing countries, 550, 555
 twinning programs and, 555
 statistics in developing countries, 550
- hematogones
 expansion, 98
 immunophenotype, 98
- hematologic malignancies
 in ataxia-telangiectasia, 281–283
 in Bloom syndrome, 284–286
 C/EBP α -dependent familial AML, 296
 Diamond–Blackfan anemia, 290–291
 dyskeratosis congenita, 292–294
 in Fanconi anemia, 278–281
 FPD/AML, 294–295
 genetic mechanisms, 276
 heritable predisposition, 276–298
 in Nijmegen breakage syndrome, 283–284
 Noonan and Noonan-like syndromes, 288–289
 severe congenital neutropenia, 296–298
- Shwachman–Diamond syndrome, 291–292
- hematopoiesis
 CD117 in, 83
 CD33 in, 83
 extramedullary, 467, 472
 tests for, 473
 treatment, 474
 fetal trisomy 21 and, 219
 MLL rearrangements and, 173
 MLL in, 210
 role of CBF, 206–208
 RUNX mutations and, 208, 209
 RUNX–CBF complex in, 295
- hematopoietic cells, leukemic transformation, 332
- hematopoietic differentiation programs, 213
- hematopoietic failure in leukemia predisposition syndromes, 278
- hematopoietic growth factors, 805–809
- hematopoietic mosaicism in Fanconi anemia, 279
- hematopoietic stem cell transplantation (HSCT), 7, 527–541
 in ALL, MRD monitoring in, 645
 in AML, 406–407
 in Burkitt lymphoma/leukemia, 390
 in CML, 463
 in Diamond–Blackfan anemia, 291
 in dyskeratosis congenita, 294
 in Fanconi anemia, 280
 in FPD/AML, 295
 growth after, 702–703
 indications for, 534
 in JMML, 288, 456, 458–460
 indications for, 458
 in MDS, 437
 neurocognitive issues and, 825
 in Nijmegen breakage syndrome, 284
 pregnancy after, 706
 in primary myelofibrosis, 475
 relapse after
 gene marking in, 605
 suicide genes for, 604
 in relapsed ALL, 374–375
 in relapsed AML, 423–424
 second, in JMML, 460
 secondary cancers after, 729–730
 in severe congenital neutropenia, 297
see also donors for HSCT
- hematopoietic stem cells
 CBF and, 210
 MLL and, 210
- hematopoietic system, gene rearrangements and, 176
- hematoxylin & eosin stain, 22
- hemocytic lymphohistiocytosis, 449
- hemoglobin concentration, 794
- hemophagocytosis, 449
- hemorrhage
 in APL, 672
 as early complication, 672
 platelet count and, 796
 platelet transfusion reduces death from, 6
- heparin, 671, 672, 678, 679
 in venous catheter, 804
- hepatic complications
 after HSCT, 538
 pre-existing, 663
 of therapy, 710–711
- hepatic symptoms and signs in ALL, 334, 337
- hepatitis, 662, 710, 777
 transfusion-associated, 800, 800, 801
- hepatomegaly
 in JMML, 446
 in primary myelofibrosis, 473
- hepatosplenic T-cell lymphoma, 101
 leukemic phase, 101
- hepatotoxicity, 681
- hereditary thrombocytopenia, 470
- heritable
 cancer risk, 276
 predisposition
 hematologic malignancies, 276–298
 to leukemias, genetic mechanisms, 277
- herpes simplex virus (HSV), 775, 777
 type 1 (HSV-1), 594
 HSV-*tk* suicide gene, 604
- herpesvirus, 9
 as gene therapy vector, 597
- heteroduplex analysis, 121, 122, 124, 127
 diagnosis of relapse vs. secondary, 127
 IGK-Kde rearrangements, 123
 sensitivity, 128
- Hispanics
 ALL in, 342
 APL in, 49, 396
- CRLF2 alteration in, 333
 secondary cancers in, 730
- histamine receptor antagonists, 479
- histochemical staining of bone marrow, 22
- histology of Burkitt lymphoma, 383, 384
- histone code alterations, 245, 249
- histone deacetylase, 625
 inhibitors, 245, 248, 249, 475, 620, 625, 753, 754
 in combination therapy, 248
- histone H3 lysine methylation, 79
- histone methyltransferases, 626
- histone modifications, 225
- Hitchings, G
 work on purines, 4, 6
 work on trimethoprim, 7
- HLA
 encoding genes, 528
 genomic map, 528
 -matched
 family donor, for HSCT, 437
 unrelated donor, for HSCT, 437
 matching in HSCT, 528, 529
- HLA-DR, 564, 573
- Hodgkin disease, nitrogen mustard in, 3
- Honduras, treatment of ALL in, 556
- honesty
 importance of, 840
 in palliative care, 847
- hope
 importance of, 840
 in relapse, 847
- hopelessness, parental distress and, 843, 845
- horseradish peroxidase, 80, 82
- hospital facilities, in developing countries, 554
 outcome and, 555, 556, 558
- host modification by gene therapy, 601–605
- HOX genes, 32, 176, 213
 in ALL, 142
 expression profiling, 39
 overexpression, 213
 in precursor T-ALL, 32
 rearrangements, 171, 176
 regulation, 210, 213
 repression of, 217
 in T-ALL, 125, 126, 146
 upregulation, 213

- in *MLL*-rearranged ALL, 173
- HOX transcription factors rearrangements and, 176
 roles, 171
- HOXA9, 754
- HPRT* mutations as biomarkers, 61
- Hsp90 inhibitors, 620, 626
- HSCT *see* hematopoietic stem cell transplantation
- Hughes, WT, work on *Pneumocystis pneumonia*, 7
- human immunodeficiency viruses (HIV) and blood transfusions, 801
- human leukocyte antigen (HLA) matching in HSCT, 528
 sibling compatibility, 7
 typing and matching, 7
- human T-cell leukemia virus-1 blood transfusions and, 800, 801
 associated leukemia/lymphoma, 100
- humor, 840
- Hungerford, DA, Philadelphia chromosome, 11
- hydrocarbons, maternal exposure, 54
- hydrocortisone, 687
- hydroxyurea, 471, 675
 in polycythemia vera, 467
 in primary myelofibrosis, 474
- hygiene education on, 842
 hand, importance of, 785
- hypercalcemia, 661, 670
- hypercellularity, 23
 MDS, 37
- hypercoagulability, 673
- hyperdiploidy, 30
 in ALL, 51, 137, 185, 340
 CD45 and, 81
 precursor B-ALL with, 30
- hypereosinophilia syndrome, 336, 475–477
- hyperglycemia, 661, 686–687
- hyperhydration, 667
- hyperkalemia, 666, 667, 669
 spurious, 674
- hyperleukocytosis, 675
- hypermethylation in JMML, 456
- hypermethylator phenotype, 245
- in ALL, 239
 in AML, 246
- hyperphosphatemia, 666, 667, 669
 spurious, 674
- hypersensitivity to asparaginase, 317–318
- hyperuricemia, 665, 667, 669
- hyperuricosuria, 6
- hyperviscosity, 673, 674
- hypnosis, during procedures, 828
- hypocalcemia, 666, 669, 669
 in tumor lysis syndrome, 666
- hypodiploidy, 30, 533
 in ALL, 137, 340
- hypoglycemia, 661, 687
- hypomethylating agents, 244–245, 246–248, 250
 in combination therapy, 248
 in JMML, 457
 in MDS, 436, 753
- hyponatremia, 686
- hypoplastic bone marrow, 99
- hypothyroidism, radiation therapy and, 702
- hyroxydurea, 11
- iAMP21, 138, 144, 175
- icasp9, 589, 604
- ICH S9, safety guidance, 619
- idarubicin vs. daunorubicin, 404
- IDH* genes, 222, 246
- idiopathic pneumonia syndrome, 538
- ifosfamide, 388
 pharmacodynamics, kinetics, and genetics, 320–321
- IG* genes, 113
 complexes, 114
 rearrangements, 116
 in B-ALL, 123, 145, 144–146, 173–174
 in B-progenitor ALL, 174–175
 cross-lineage, 125
 during lymphoid differentiation, 116–119
 PCR analysis, 120
 junctional regions in, 635, 637, 634–638
 secondary, 116, 118
 somatic hypermutations in, 116
- IG/TCR* genes combinatorial diversity, 115
 rearrangements, 114
- aberrant and oncogenic, 125–126
 in ALL, 123–124
 in AML, 125
 antigen specificity and, 113, 115–116
 clonality detection based on, 119–122, 126–128
 diagnostic applications, 126
 during lymphoid differentiation, 116–119
 frequencies, 124
 in lymphoid leukemia, 113, 126
 processes, 113–119
 secondary rearrangements, 116, 117
- IGH@* gene in ALL, 145, 175
- IGH@-CRLF2* fusion, 174
- IGH@-ID4* fusion, 146
- IGH@-MYC* in B-ALL, 144–146
- IGH@-PAX5* fusion, 145
- IgM B-cell receptor, 76, 82
- IKZF* genes, 138, 221
 in ALL, 182
 alterations, in ALL, 178
 in precursor B-ALL, 332
 deletions, 140, 171, 175
 polymorphisms, 60, 60, 321
 and risk of ALL, 185, 333
 susceptibility allele, 298
- imatinib, 9, 11, 171, 620
 action, 250, 425
 in ALL, 140, 186, 354, 533
 in chronic eosinophilic leukemia, 476
 clinical trials, 461
 in CML, 250, 461–462
 large granular lymphocytes and, 100
 in polycythemia vera, 468
 resistance to, 477
- immune competence, B-cell maturation, 76
- immune response, appropriate, delayed exposure to infection and, 57
- immune system impairment, infections and, 772
 modification, gene therapy for, 601
 recognition of tumor cells, 582–584
- immune-mediated cytotoxicity, 563
- immunization, 786
 anti-tumor, 600
see also vaccination
- immunoassays for fungal infections, 776
- immunoblotting, in diagnosis of ataxia-telangiectasia, 282
- immunodeficiency
 in ataxia-telangiectasia, 281, 283
 in Bloom syndrome, 285
 prolonged, after HSCT, 539
 and risk of Burkitt lymphoma/leukemia, 386
 in survivors, 711
- immunofluorescent microscopy, 80
- immunogenicity of MoAbs, 573
- immunogenotype, childhood leukemias, 122–126
- immunoglobulins
 B-lineage and, 82
 encoding genes
 in Burkitt lymphoma/leukemia, 385
see also IG genes
 in JMML, 448
 molecules
 junctional diversity, 116
 repertoire, 115, 115–116
 structure, 113
 surface membrane-bound (SmIg), 113
- immunohistochemical assays
 bone marrow, 22, 80
 procedures, 82
- immunophenotypes
 in AML, MRD assays and, 410, 640, 648
 AML with minimal differentiation, 403
 AML with t(8;21), 400
 in APL, 403
 Burkitt lymphoma/leukemia, 384, 383–385
 leukemia, 2
 for MRD studies, 639
 multilineage lymphomyeloid, 213
 in relapsed ALL, 369
- immunophenotypic classification, 29–30
- immunophenotyping, 78
 of ALL, 338–340
 of AML, 397
 B-ALL, 85
 Burkitt lymphoma, 383
 future directions, 102
 methods, 80–84
 MRD assays base on, 638
 panel, 80, 82
 in ALL, 338

Index

- immunosuppression
 agents
 in chronic GVHD, 540
 in GVHD prophylaxis, 539
 chemotherapy-induced, 7
Pneumocystis pneumonia and, 7
 pre-HSCT, 532
 immunosuppressive therapy, in MDS, 436
 immunotherapy, 582–589
 adjuvant, 783–784
 in AML, 412, 425
 modulating therapies, 783
 immunotoxins, 390, 566
 anti-CD19, 568
 incidence
 adrenocortical insufficiency, 687
 ALL, age at diagnosis and, 520
 AML, 396, 396
 APL, 396
 ataxia-telangiectasia, 281
 Burkitt lymphoma/leukemia, 386
 childhood cancer, geographic variation, 549
 CNS leukemia, 676
 coagulopathy, 672
 Diamond–Blackfan anemia, 290
 early complications, 660
 essential thrombocythemia, 468
 ethnic and racial differences
 in Bloom syndrome, 284
 in Fanconi anemia, 278
 in Nijmegen breakage syndrome, 283
 GVHD, 459
 hematologic malignancies, 431
 hyperleukocytosis, 673
 JMML, 430, 445
 late complications of GVHD, 539
 leukoencephalopathy, 684
 leukostasis syndrome, 673
 mastocytosis, 477
 MDS, 430
 mucositis, 679
 Noonan syndrome, 288
 osteonecrosis, 685
 Ph⁺ CML, 460
 polycythemia vera, 464
 post-transfusion hepatitis C, 801
 primary myelofibrosis, 472
 relapse in AML, 408
 secondary cancers, 712, 724–725
 Shwachman–Diamond syndrome, 291
 thrombotic complications, 677
 incidence trends in leukemia, 49–50
 income, family, access to care and, 551
 infant ALL, 353
 infants
 chemotherapy in, 662
 leukemia in, 56–57
 etiology, 56–58
 infection, 772–786
 acute leukemia and, 6
 after HSCT, 537
 ALL and, 57
 in ALL, 334, 344
 in AML, 411
 in ataxia-telangiectasia, 281
 catheter-related, 6, 803–804
 as cause of death, 6
 childhood leukemias and, 58
 in chronic GVHD, 540
 exposure pattern, 57
 fungal, 6
 hepatitis C, 710
 myeloablative therapy and, 527
 pre-existing, 663
 prevention, 842
 nursing care and, 841
 secondary, 6
 in severe congenital neutropenia, 296, 297
 susceptibility to, in Down syndrome, 506
 therapy-related, in ALL, 349, 353
 transfusion-associated, 800, 800–802
 viral, 7
 imitates JMML, 449
 infectious diseases, mortality from, in developing countries, 550
 infertility
 after HSCT, 539
 alkylating agents and, 705
 influenza, 785
 information
 healthy lifestyle, 846
 need for, 840, 842, 843
 in palliative care, 848
 in relapse, 847
 patient/parent handbook, 844
 receptiveness to, 840
 reinforcing, 845
 inherited bone marrow failure in MDS, 432
 inherited genetic variation, risk of ALL and, 185
 inosine triphosphate pyrophosphatase polymorphisms, 3
 inotuzumab ozogamicin, 9, 620, 623
 insecticide exposure, 59
 integrin inhibitors, 620
 intensification therapy, 345
 in ALL, 349–350, 522
 in AML, 406
 MRD detection as criterion, 649
 intent to treat, 5
 interferon- α , 11
 in CML, 12, 461
 in JMML, 457
 in polycythemia vera, 467
 in primary myelofibrosis, 474
 interferon-gamma, recombinant human, 784
 interindividual variability, 321
 in drug response, 343
 interleukins, 809
 1 β , in JMML, 449
 2, 603
 2 receptor, 564
 3 receptor, 572
 10, in JMML, 449
 15, 321
 modified T-cells, 603
 SNPs in, 321
 International Outreach Program, St Jude Children's Research Hospital, 555
 results for ALL, 556–557
 results for AML, 557–559
 results for Burkitt lymphoma/leukemia, 557–559
 International Prognostic Scoring System for MDS, 436, 436
 International Randomized Study of Interferon and STI571 (IRIS), 12
 intracellular NOTCH1 protein (ICN1), 183
 intrachromosomal amplification of chromosome 21 (iAMP21), 144, 175
 intracranial myeloid tumors, 676
 intrathecal therapy
 in AML, 407
 in Burkitt lymphoma/leukemia, 389
 CNS status and, 338
 leukoencephalopathy and, 684
 MoAb-based, 574
 sequelae, 706
 triple, 350
 in relapsed ALL, 371
 inversion
 definition, 135
 inv(3)/t(3;3), 155
 inv(7)(p14q34), 125
 inv(14)(q11q32), 125
 inv(16), 152, 206, 400
 inv(16) cytogenetic abnormalities, 9
 inv(16)(p13;q22), 35, 90, 742, 749
 inv(19)(p13.3q13.4), 140
 ionizing radiation
 hypersensitivity to, 278, 279, 287
 paternal exposure, preconceptually, 53
 X-rays
 in utero, 53
 postnatal, 53
 IQ score, neurotoxicity and, 823–825
 iron overload, 796
 irradiation
 of blood products, 796
 in CNS relapse, 372–373
 cranial
 CNS tumors and, 712
 growth and, 701, 709
 leukoencephalopathy and, 684
 neurologic sequelae, 706–707
 craniospinal, 9
 growth and, 701
 early use, 3
 immunodeficiency and infection, 772
 neuraxis, 9
 regimen for HSCT, 424
 resistance to, nitrogen mustard used in, 3
 in testicular relapse, 373
 thyroid function and, 702
 total body, 7, 532
 isochromosomes, 135
 isocitrate dehydrogenase 1, 222
 isolation from infection, 784–785
 isotype-dependent C exons, 113
 JAK, 22
 JAK2 inhibitors, 475
 JAK genes, 205
 in ALL, 138
 in DS AMKL, 219
 in essential thrombocythemia, 468
 mutations, 142
 CRLF2 alterations and, 174, 181
 in polycythemia vera, 464
 in primary myelofibrosis, 472
 in T-ALL, 147

- JMML *see* juvenile myelomonocytic leukemia
- Jamshidi needle, 22
- Janus kinase (JAK) tyrosine phosphatase, 81
 in AMKL, 220
- Japan, leukemia incidence, 53
- Japanese Childhood AML Cooperative Study AML99, 400
- jaundice, 662
- junctional diversity, 116
- junctional region-specific oligonucleotide probes, 128
- juvenile myelomonocytic leukemia (JMML), 38, 429, 445–460
 characteristics, 23, 445, 446, 447
 in neurofibromatosis, 287, 446
 in Noonan syndrome, 289
 incidence, 431
- kappa-deleting element (Kde), 114, 117
 rearrangements, 118, 123, 124
- Karon, M, advocated truthfulness, 7
- karyotype
 alterations, in ALL, 168
 complex, 158
 leukemic cells, 30
- karyotyping, value in ALL, 340
- killer cell immunoglobulin-like receptor (KIR)
 genomic map, 528
 mismatching, 528, 541
- KIR* genes, 529
- KIT* genes, 400
 in AML, 152, 408
 in mastocytosis, 477
- Knudson's "two-hit" model, 453
- Kostmann
 granulocytic leukemia, 51
 syndrome, 296
 heritable predisposition, 277
- Krivit, W, Down syndrome work, 9
- laboratory findings
 in ALL, 334, 336–338
 in AML, 398
 in Burkitt lymphoma/leukemia, 388
 in coagulopathy, 672
 in essential thrombocythemia, 470
- in JMML, 445–448
 leukostasis syndrome, 674
 in polycythemia vera, 465–466
 in primary myelofibrosis, 473
- lactate dehydrogenase, leukemic cell burden and, 337
- lactoferrin, as marker of maturation, 79
- Landsteiner, K, identification of blood groups, 5
- large granular lymphocyte leukemia, 100
 immunophenotype, 100
- large granular lymphocytes, 100
- latency of treatment-related leukemias and MDS, 724, 747–750
- lead, parental exposure, 54
- Leder stain, 22
- Legius syndrome, 452
- lenalidomide, 753
- lentiviral vectors, 594
- lentivirus, 594
- LEOPARD syndrome, 450
- lestaurtinib, 620
- leucovorin rescue, 310, 352
- leukapheresis
 in ALL, 344
 in AML, 411
 for hyperleukocytosis, 675
 results, 345
- leukemia research
 candidate gene approach, 58
 future trends, 61
 genome-wide association studies, 59–61
 SNPs, 58–59
- leukemia stem cells in AML, 397
- leukemia(s)
 in ataxia-telangiectasia, 281
 in Bloom syndrome, 285
 cellular origins, 1
 chromosomal abnormalities, 2
 classification, 2, 9, 21, 22, 28–39, 72
 future trends, 39
 modern approach, 21, 28
 coining of term, 1
 congenital, 94
 CBF, 10
 development of, host polymorphisms and, 3
 diagnosis, 21, 22, 72
 in Down syndrome, 503–513
 in dyskeratosis congenita, 293
 epigenetic changes, 3
 establishing diagnosis, 23
- familial platelet disorder and, 294, 295
 in Fanconi anemia, 279
 first treatments, 3
 frequency, by country, 549
 gene expression profiles, 3
 gene therapy-induced, 606–607
 genetic changes, 3
 identification, flow cytometry for, 80
 immunophenotype, 2
 mixed lineage, 37
 Moabbased therapeutics in, 564
 as model for drug development, 616
 in neurofibromatosis, 287
 in Nijmegen breakage syndrome, 284
 pathobiology, 39
 pathogenesis, 332
 predisposition syndromes, 278
 refractory, 11
 research, future trends, 186
 in severe congenital neutropenia, 297
 in Shwachman–Diamond syndrome, 291
 subtypes, 3
 susceptibility allele inheritance and, 298
 therapy-related, 723–755
 management algorithm, 750
 undifferentiated, 128
- leukemia-initiating cells in AML, 397
- leukemic blasts, 81, 96
 in ALL, 339
 in AML, 397
 in APL, 402
 chromosomal changes, 2, 332
- leukemic cells
 access to CNS, 676
 burden, 339
 lactate dehydrogenase and, 337
 reducing, 344, 411
 cytogenetics in AML, 147
 karyotypes, 30
 in leukostasis, 674
 lysis, 337
- leukemic growth, folic acid and, 4
- leukemic infiltration of other organs, 663
- leukemic masses, 663
- leukemic transformation, 332
- leukemogenesis
 in ALL, 177, 333
 in AML in utero, 397
- chromosomal alterations and, 168, 205
 in Down syndrome, 509, 510, 512
 ETV6–RUNX1 and, 170
 gene therapy-related, 606–607
 HOX proteins and, 172
 HOX gene regulation in, 213
 inherited genetic variation and, 185
 MLL rearrangements and, 173
 MLL-mediated, 213
 PML–RAR α -mediated, 216
 RUNX, 209
 stepwise nature, 178
 TCF3–HLF and, 172
 treatment-induced, 725
 in trisomy 21, 218
 in utero, 333, 509
- leukoencephalopathy, 684
- leukocytes
 expression profiles, 81
 subsets, staining discriminates, 2
- leukocytosis
 in chronic leukemia, 23
 in chronic myeloproliferative neoplasms, 23
 in essential thrombocythemia, 471
 in JMML, 38
 leukemia distinguished from, 1
- leukoencephalopathy, 661, 683
- leukopenia, 23
- leukostasis, 661, 673, 674
 pulmonary, 675
 syndrome, 675
- leucovorin rescue, renal impairment and, 663
- licensing of new drugs, 617
- lidocaine, 819
- lifestyle education for survivors, 846
- lifestyle factors, 54–55
- Li-Fraumeni syndrome, 730
- LIM proteins, actions in T-ALL, 176
- lineage
 analysis of differentiation, 126, 128
 assessment, cytochemical staining, 23
 assignment, 22
 commitment, AML classified by, 32
 development, 80
 identification

Index

- lineage (*cont.*)
 immunophenotyping panel,
 80
 screening panels, 338
 megakaryoblastic, in AML
 subtypes, 34
 promiscuity, *MLL* gene
 rearrangements and, 213–214
 switches, 37, 97, 421
- linituzumab, 563, 571
- liposomes, as vectors, 597
- Lissauer, H, used Fowler's
 solution, 3
- LMO* genes
 overexpression, 172
 in T-ALL, 125, 126, 147, 176
- lonafarnib, 620
- Loutit, JF, total body irradiation,
 7
- low- and mid-income countries
see developing countries
- lumbar puncture
 analgesia, 819, 829
 anticoagulants and, 678
 diagnostic, 338, 672
 platelet count and, 798
 preparing for, 841
 traumatic, 338, 676, 798
- lumiliximab, 564, 570
- lung biopsy, 776
- lung function, chronic GVHD
 and, 539
- LYL* genes
 chromosomal aberrations in
 T-ALL, 125
 expression in T-ALL, 126
 expression profiling, 39
 in precursor T-ALL, 32
 in T-ALL, 147
- LYL1* overexpression, 176
- lymph nodes in ALL, 334, 337,
 337, 670
- lymphoblastic lymphoma
 involving bone marrow, 23
- lymphoblastic T-cell
 malignancies, 124
- lymphoblasts
 characteristics, 23, 24
 count, 23
 identified, 2
 staining, 24
- lymphocyte maturation, CD45
 and, 81
- lymphoid blasts, 23
 crisis, 249
- lymphoid differentiation, *IG/TCR*
 rearrangements during, 116, 118
- lymphoid leukemias, *IG/TCR*
 rearrangements in, 113, 126
- lymphoid malignancies, *MYC*
 rearrangement in, 173
- lymphomagenesis, 385, 386
- lymphomas
 in ataxia-telangiectasia, 281
 in Bloom syndrome, 285
 frequency, by country, 549
 malignant, frequencies, 122
 morphologic, immunologic,
 and cytogenetic (MIC)
 classification, 383–384
 in Nijmegen breakage
 syndrome, 284
 nitrogen mustard in, 3
 Revised European–American
 Lymphoma (REAL)
 classification, 384
 as target for treatment in
 developing countries, 552
- lymphoproliferations, diagnosis,
 126
- MAD–MAX dimer, 385
- maintenance therapy in ALL,
 522
- major histocompatibility
 complex (MHC), role in antigen
 presentation, 582
- Malawi, Burkitt lymphoma/
 leukemia in, 558
- malignancy, secondary, 711–713
 HSCT and, 539
 treatment-related, 723–755
- malnutrition, 660
- MAP kinase dysregulation, 286
 neurofibromatosis type 1, 287
 in Noonan syndrome, 289
- MAPK signaling, 220
- marijuana, maternal use, 55
- markers for MRD studies
 in ALL, 639, 639–640
 in AML, 640, 640
- mastocytosis
 classification, 478–479
 systemic, 477
 WHO classification, 478
- maternal age and childhood
 cancer, 55
- maternal reproductive history
 and childhood leukemia, 55
- maturation, leukemia
 classification by, 32
- “mature” B-ALL
 chromosomal abnormalities,
 144
- flow cytometry, 81
 immunophenotype, 86–87
- MAX (MYC-associated factor
 X), 174
- maximally tolerated dose
 multiagent regimens, 619
 phase I trials define, 618
- MCL1, glucocorticoid resistance
 and, 261, 262
- MDM2* polymorphisms, 734
- MDR* genes, 320
 therapeutic use, 604
- MDS *see* myelodysplastic
 syndrome
- measles vaccination, 7
- MECOM* gene activation, 155
- mediastinal structures,
 compression, 671, 672, 670–672
- MEF2D-DAZAP1* fusion
 transcript, 139
- megakaryoblastic leukemia
 diagnosis, 80
 differentiating, 92
 staining, 24
- megakaryoblasts
 in AML subtypes, 34
 characteristics, 23, 24
 staining, 27
 in TMD, 218
- megakaryocyte
 dysplasia, 23, 38
 hyperplasia, 23
- megakaryocytic
 -erythroid progenitor, 92
 maturation, 79
 and differentiation, 80
- melphalan, as myeloablative
 therapy, 459
- memory B-cells, 77
- menarche, ALL treatment and,
 705
- meningitis, 778
- mepolizumab, 477
- mercaptopurine, 8
 in ALL, 521
 cellular drug resistance, 266,
 267
 in continuation treatment in
 ALL, 351–352
 early use, 4
 hypoglycemia and, 687
 in hyperdiploid ALL, 269
 in JMML, 457
 low-cost regimen, 553
 metabolism, 312
 polymorphisms affect, 3
- pharmacodynamics, kinetics,
 and genetics, 311–313
 precursor B-ALL sensitivity
 to, 30
 secondary cancers and, 734
 toxicity, 313
- mesenchymal cells in
 asparaginase rescue, 263, 319
- metabolic complications, early,
 663–670
- metal dusts and fumes, maternal
 exposure, 54
- metamyelocytes, 79
- methadone, 817
- methicillin, 6
- methotrexate, 8, 266, 268
 in ALL, 521
 bone mineralization and, 709
 in Burkitt lymphoma/
 leukemia, 388, 558
 cellular drug resistance, 266,
 268
 mechanisms, 268
 in continuation treatment in
 ALL, 351–352
 drug–drug interactions, 319
 early use, 4
 guidelines for use, in Brazil,
 559
 high-dosage, in ALL, 349
 in hyperdiploid ALL, 269, 340
 in intensification therapy in
 ALL, 349
 for intracerebral myeloid
 tumors, 677
 low-cost regimen, 553
 mucositis and, 681
 neurocognitive effects, 825,
 827
 neurologic sequelae, 707
 pharmacodynamics, kinetics,
 and genetics, 309–311
 postinduction intensification,
 9
 precursor B-ALL sensitivity
 to, 30
 resistance to, 258
 sensitivity to, in Down
 syndrome, 506
- methylated CpG amplification,
 242, 243
- methylation
 aberrant
 in adult ALL, 240, 239–242
 in CML, 248
 impact of, 241
 in pediatric ALL, 242
 analysis, assays for, 242
 arrays, 242
 impact on prognosis, 240, 241
 patterns
 age and, 242

- in ALL, 240, 242
 profile
 in ALL, 239
 in AML, 246
 studies
 in chronic lymphocytic leukemia, 245
 in MDS, 246
 in pediatric ALL, 244
 single gene, in ALL, 239
 therapy targeted at, 244–245
- methylation inhibitors, 625
- methylator phenotype, CpG island, 239
- methyl-bis-(β -chloroethyl) amine in lymphoma, 3
- methylphenidate, 827
- methylthiazol-tetrazolium (MTT)-based assays, 257
- methyltransferase
 encoding gene mutations, 246, 733
 in CML, 249
 inhibitors, 475, 620, 625, 627
 in JMML, 456
- Mexico, management of pediatric cancer in, 551
- mice
Arid5b knockout, 185
Cbf genes, 206, 208, 209
Runx1, 208
Cbl-deficient, 455
cdkn2a mutant, 183
Cebpa knockout, 224
 clonal evolution studies, 184
Dnmt1 mutations, 225
 drug screening in, 616
 AMKL-DS studies, 218
GATA1 knockout, 219
Mll knockout, 210
MLL studies, 173, 740, 741
MYC gene studies, 385
Nfl-deficient, 453
NPM-ALK models, 221
Pax5 studies, 178
Ras studies, 453
RASi gene mutations, 224
Rbm15 knock-out, 220
RUNX-null, 295
 tumor suppressor genes in, 183
 tumor vaccine models, 599
- microsatellite instability, 61
- microtubules, vinca alkaloids and, 263
- midostaurin, 620
- milatuzumab, 564, 572
- minimal residual disease (MRD), 2, 9
 in ALL, 525
- HSCT and, 533, 535
 in AML, 410
 bone marrow transplantation and, 535, 536
 in APL, 410
 assays, 410, 422
 detection by PCR, 368
 gene transfer therapies aimed at, 593
 methylation studies of, 241
 as prognostic factor, 343, 368, 642
 in relapsed AML, 422
 risk stratification and, 525
 testing and monitoring, 636, 641, 644, 646, 632–649
 therapeutic efficacy assessed by, 616
- minor histocompatibility antigens, 583
- mitoxantrone, 404, 726
- mixed lineage leukemia, 403
 molecular genetics, 210–214
 and partial tandem duplications, 214
 secondary mutations, 214
- mixed phenotype acute leukemia, 88, 94, 403
 diagnosis, 95
 immunophenotype, 95
- MKL1, actions, 220, 221
- MKL1-RBM15 fusion product, 220
- MLL
 actions, 172, 210
 -mediated leukemogenesis, 213
 structure, 211
- MLL* genes, 31, 35, 210
 in ALL, 138, 332
 in AML, 150
 CD79 and, 82
 fusion partners, 212, 213, 740
AF10 fusion, 154
AF4 fusion, 214, 333
AF9 fusion, 213
ELL fusion, 212, 214
ENL fusion in precursor T-ALL, 32
GAS7 oncogene, 213
 in PCR assays, 633
 rearrangements, 51, 142, 153–154, 172, 205, 211, 739–741, 745
 AML classified by, 400
 cellular drug resistance and, 257, 262, 267
 emergence during chemotherapy, 745
 in ALL, 213, 340
- in AML, 185, 210, 213, 401, 409
 in B-ALL, 172–173
 in infant leukemias, 51, 56
 in leukemogenesis, 177, 213
 in secondary leukemias, 333
 in T-ALL, 176
 leukemia-associated, 317
 on chromosome 11q23, 210–214
 partner genes, 143
 PCR analysis of, 633
 recombinome, 740
 partial tandem duplication (PTD), 154
 fusion protein, 214
 tandem duplication, 214
 in therapy-induced leukemia, 56
 in therapy-related AML, 36
 in utero exposures and, 56
- Moabs *see* monoclonal antibodies
- modal number, 135
- molecular analysis in ALL, 30
- molecular classification of ALL, 30–32
- molecular cytogenetics
 in AML, future trends, 225
 cytogenetically normal AML, 220–225
- molecular genetics
 alkylating agent-induced changes in, 736–739
 in ALL, 182–186
 PCR assay of, 642
 in AMKL, 217–220
 in AML, 204–225
 PCR assay of, 647–648
 studies, 399
MLL gene, 210–214
 targets for PCR, 633
 topoisomerase II
 poison-induced changes in, 739–744
 of treatment-related leukemia, 744
- molecularly targeted therapy, 624–627
 for treatment-related leukemias/MDS, 753
- monoblastic leukemias
 chromosomal abnormalities, 91
 leukostasis syndrome in, 675
- monoblastic neoplasms, immunohistochemistry, 91
- monoblasts, 675
 in AML subtypes, 33
 characteristics, 23, 24
 staining, 24, 27
- monoclonal antibodies (MoAb), 375–376, 563–574, 623–624
 agents
 anti-CD19, 568
 anti-CD20, 568–569
 anti-CD22, 569–570
 anti-CD25, 570
 anti-CD33, 570–571
 clinical trials of, 566–573
 cytotoxicity, 565
 mechanisms of, 563–566
 side effects and limitations, 573–574
 bispecific, 565
 conjugates, 564, 565
 polyspecific, 566
- monocyte maturation, 78
 and differentiation, 78–79
- monocytes
 in AML subtypes, 33
 in JMML, 449
- monocytic component in AML, 33
- monocytic differentiation, 34
 in AML subtypes, 35
 in therapy-related AML, 36
- monocytosis, 23
 in JMML, 447
- monosomy 5, 7, 736, 737–738
 AML and, 397
 in JMML, 448, 457
 in MDS, 429, 432, 434
 in ALL, 141
 in AML, 149, 155
 FISH, 150
- morphine, 816
- morphologic analysis, 22–28
 in relapsed ALL, 367
 specimen preparation, 22
- morphologic classification
 in ALL, 28–29
 MDS, 37
- morphologic diagnosis, 22–28
- morphologic features
 of APL, 33
 in diagnosis, 91
 erythroleukemia, 91
 healthy pediatric B-cells, 98
 MDS, 38
- morphologic, immunologic, and cytogenetic (MIC) classification, 30
 acute leukemias of ambiguous lineage, 36–37
 in AML, 32, 33, 34
 in AML subtypes, 34, 35

Index

- morphologic, immunologic, and cytogenetic (*cont.*)
 in AML with myelodysplasia, 35
 in APL, 33
 blastic plasmacytoid dendritic cell neoplasms, 37
 lymphoma, 383–384
 myeloid sarcoma, 37
 therapy-related AML, 36
- mortality
 age-adjusted, for AML, 396
 child, in various countries, 550, 551
 supportive care and, 660
- moxetumomab pasudotox, 620, 623
- MOZ genes, 155
 in AML, 148
- MPL
 in AMKL, 220
 in essential thrombocythemia, 469
- MPL genes, 205, 220, 295, 468
 in primary myelofibrosis, 472
- MPO *see* myeloperoxidase
- MPO polymorphism, 59
- MRD *see* minimal residual disease
- MRN complex, 282, 284
- MRP1 *see* multidrug resistance protein
- MTHFR polymorphisms, 58, 733
- mTOR inhibitors, 620, 626
- MTR polymorphisms, 58
- MTRR polymorphisms, 58
- mucosal lesions, infections and, 772
- mucositis, 662, 679–681, 776, 844
 after HSCT, 537
 care in, 844
- multiagent therapy, 8
- multidrug resistance, 370
 AML relapse and, 423
 -associated protein (MRP), 259, 268
 drugs to target, 627
- multikinase inhibitors, 620
- multi-organ impairment, 7
- multiple myeloma, incidence and distribution, 124
- multiplex pyrosequencing assays, 242
- muromonab, 564, 567, 623
- mustard gas, trials with, 3
- mutations
 in AML, 397, 408
 in Bloom syndrome, 285
 in CEBPB-dependent familial AML, 296
 class I, 205
 class II, 205
 in DS TMD/AMKL, 508, 509
 in dyskeratosis congenita, 292
 in essential thrombocythemia, 468
 family cancer syndrome, 730–731
 in Fanconi anemia, 278
 in FPD/AML, 295
 gain-of-function, 276
 inherited, 276
 in JMML, 450–455
 leukemia-associated, 208–210
 in mastocytosis, 477
 multiple, for leukemogenesis, 205, 332
 in neurofibromatosis type 1, 287
 in Noonan syndrome, 288, 289
 in primary myelofibrosis, 472
 in RASopathies, 286
 in severe congenital neutropenia, 297
 in Shwachman–Diamond syndrome, 292
 secondary
 in CBF leukemia, 209–210
 in mixed lineage leukemia, 214
 topoisomerase II poisons and, 739–744
 tumor suppressor genes, 385
- MVP/LRP, anthracycline resistance and, 264
- MYB in T-ALL, 146
- MYC genes, 28, 340
 in ALL, 145
 in Burkitt lymphoma/leukemia, 384, 385
 rearrangements, in B-ALL, 173–174
 in T-ALL, 125, 147
- MYC protein
 in B-ALL, 145
 overproduction, 385
 roles, 174
- MYC proto-oncogene, NPM and, 222
- MYC–MAX heterodimers, 385
- myeloablative therapy, 7, 532
 choice of, 532
 growth after, 703
 in JMML, 459
 in MDS, 436, 437
 mortality in, 527
- second, 535
 secondary cancers and, 730
- myeloblastoma, 398, 677
- myeloblasts, 23, 33
 in AML, 33, 34
 characteristics, 23, 24
 count, diagnosis based on, 23
 expression profiles, 78
 identified, 2
 staining, 24, 27
- myelocytic maturation, 78, 79
 and differentiation, 78–79
- myelodysplasia
 classification, 30
 cytological features, 433
 -related changes, AML with, 35
- myelodysplastic syndrome (MDS), 36, 37–38, 429–437
 adult vs. pediatric, 429
 azacytidine trials in, 246–247
 bone marrow transplantation, 536
 characteristics, 23
 chromosomal abnormalities, 149
 classification, 21
 decitabine in, 247–248
 in Down syndrome, 34, 508
 dysplastic features and, 23
 epigenetics, 245–248
 incidence, 431
 preleukemic, therapy-related, 36
 treatment-related
 clinical presentation, latency, and diagnosis, 750, 747–750
 cytogenetic and molecular aberrations, 738–739
 management algorithm, 750
 treatments and outcome, 751–753
 vs. AML, 435
 algorithm, 435
- myelofibrosis
 in AML subtypes, 34
 primary, 471–475
- myeloid blast crisis, 249
- myeloid blasts, 23
- myeloid cell tumors, 676
- myeloid differentiation
 in AML, 204
 in APL, 402
 CEPB β and, 296
 minimal, in AML, 33
- myeloid leukemia
 of Down syndrome (ML-DS), 34, 88, 429, 430, 432, 508
 epigenetic therapy, 246–248
 in Fanconi anemia, 430, 431
- leukostasis in, 673
 incidence, 431
 risk of tumors, 676
- myeloid neoplasia, 430
 WHO classification of, 444
- myeloid neoplasms, therapy-related, 88
- myeloid neoplasms, treatment-related, 36
- myeloid proliferations associated with Down syndrome, 38
 immunophenotyping, 93–94
- myeloid sarcoma, 37, 88
- myeloid-associated antigen expression in ALL, 339
- myeloid-to-erythroid cell ratio, 23
- myelopathy, 661, 684
- myeloperoxidase (MPO), 24
 in AML, 26
 as marker of maturation, 79, 83
 staining, 24
 applications, 24
- myelopoiesis, disorders of, severe congenital neutropenia, 296
- myeloproliferative disorders (MPD), 444–480
- myeloproliferative neoplasm, characteristics, 23
- myelosuppressive agents, 6
- Nägeli, O, identified myeloblast and lymphoblast, 2
- naphthol AS-D chloroacetate, 24
- narcotics, 5
- natural killer cells
 activity in HSCT, 530
 in graft-versus-leukemia effect, 425
 in transplantation, 541
 large granular lymphocytes, 100
 leukemia, 97
- nausea and vomiting, controlling, 829–830
- NBN gene, 283, 284
- N-CoR co-repressor complex
 CBF-mediated transcription and, 208
 lymphoid development and, 170
- near-haploidy, in ALL, 137, 335, 340

- needs framework, supportive care, 839–848
- nelarabine, 9, 375, 620, 622
- neoplasms
 hematopoietic and lymphoid, diagnosis, 80
 precursor B-cell, 385
 second, 711–713, 724
- Neumann, E, associated leukemia with bone marrow changes, 1
- neuro-cardio-cutaneous facial syndromes, *see* RASopathies
- neurocognitive deficits, after therapy, 823–827
 interventions, 827–828
- neurofibromatosis, 286–288
- neurofibromatosis type 1 (NF1), 51, 451, 452–454
 and JMML, 446
 heritable predisposition, 277
- neurologic complications, on-therapy, 682–685
- neurologic sequelae to therapy, 706–707
- neuron-specific enolase, 92
- neuropathic pain, 815, 817
 adjuvant analgesics, 817–818
- neuropathy, vincristine-induced, 349
- neuropsychological consequences, 8
- neuropsychologic impairment
 global, 823–825
 specific, 825–826
- neurotoxicity
 intrathecal AraC and, 315
 methotrexate-induced, 352
 new nucleoside analogues and, 622
 vincristine-associated, 320
- neutropenia
 cyclic, 297
 and CNS infections, 778
 definition, 779
 ear, nose, and throat infections and, 776
 and fever, 6, 779–781
 infection and, 772, 779–781
 bloodstream, 773
 pulmonary, 775
 lack of inflammatory response in, 774, 778, 779
 prophylaxis, 805–807
 severe congenital, 296–298
 heritable predisposition, 277
 typhlitis and, 777
- neutrophilia, 23
 in CML, 38
- neutrophils, 79
 expression profiles, 78
 infections and, 772
 level of, and infection, 6
 recovery of, outcome and, 6
- NF1* tumor suppressor gene, 287
- Nijmegen breakage syndrome, 283–284
 aberrant *TCR* rearrangements in, 125
 heritable predisposition, 277
- nilotinib, 12, 250, 462, 620, 624
- N*-nitroso compounds, 55
- nociceptive pain, 814
- NOL1-E2A* fusion, 140
- non-erythroid cells in AML, 33
- non-governmental organization cancer units in developing countries, 555
 funding from, 556
 support access to care, 554
 in Brazil, 553
- non-Hodgkin lymphoma, 23, 386
 incidence and distribution, 124
- non-ionizing radiation, 54
- non-specific esterase stain, 24
- non-steroidal anti-inflammatory drugs, 815
- non-viral vector systems, 597
- Noonan syndrome, 288–289, 450
 heritable predisposition, 277
 JMML in, 446
- Noonan-like syndrome, 288–289, 451
 heritable predisposition, 277
 JMML in, 446
- normal-karyotype ALL, 137
- NOTCH* genes in T-ALL, 183
- NOTCH* proteins, actions, 183–184
- NOTCH1* inhibitors, 620
- NOTCH1:CSL* complex, 183
- Nowell, PC, Philadelphia chromosome, 11
- NPM (nucleophosmin), 221
 actions, 221, 222
 in cancer, 221
 in cytogenetically normal AML, 221–222
- NPM* genes
 in AML, 149, 409
- mutated, 35
- NPM-ALK* fusion oncogene, 222
- NQO1* gene polymorphisms, 59, 733
- NR3C1* gene, 320
- nuclear bodies, roles, 215
- nuclear fallout
 studies, 53
 weapons tests, 53
- nuclear power plants, studies of leukemia near, 53
- nucleic acid amplification testing, 801
- nucleofection, 597
- nucleophosmin, *see* NPM
- nucleoside analogues, 266
 cellular drug resistance, 266
 novel, 375, 621–622
- nucleoside transporters
 polymorphisms, 3
- NUP214-ABL1* fusion, 183
- NUP98* gene, 156, 742, 749
- nursing care, 839, 839–848
- nutrition
 during treatment, 841
 maintaining good, 660
 standard of, at diagnosis, complications and, 660
- obatoclax, 375
- obesity
 after ALL therapy, 704–705
 in APL, 402
 complications due to, 660
 dosing and, 660
- oblimersen, 620, 626
- ocular
 involvement in ALL, 334, 335
 late effects, 707
- ofatumumab, 620, 623
- oligoclonality, 127, 636
 B-ALL, 123
 T-ALL, 125
- oligonucleotides, antisense, 598, 754
- oncogenes
 mechanisms, 332
 transcription factors as, 168
 translocations and, 168
- oncolytic viruses, 597
- oncoretroviral vectors, 593
- ondansetron, 830
- opioids, 816–817
 dosing, 816
- side effects, 818
 sustained release, 816
 as syrups, 816
- oral
 complications, 345, 775, 776
 side effects, 709
- osteonecrosis, 662, 685, 710
 therapy-related, 524
- other ambiguous lineage leukemias, 94, 96
- outcome
 in ALL, 185
 age at diagnosis and, 520, 523
 in El Salvador, 556
 MRD predicts, 642, 643, 647
 in SGH-II study, 557
 in ALL-DS, 505
 ALL subtypes, 341
 in AML, 535–536
 in developing countries, 559
 MRD predicts, 648, 649
 in APL, 410
 in Burkitt lymphoma/leukemia, 389, 390
 cancer, in Brazil, 553
 cellular drug resistance and, 257
 cognitive
 chemotherapy and, 824
 cranial irradiation and, 824
 determinants of, 5
 in DS AML, 508, 510
 heterogeneity of, 3
 host factors affecting, 3
 HSCT and
 in ALL, 533–535
 in AML, 10, 408–410
 source of stem cells and, 530–531
 of HSCT
 in AML, 424
 in CML, 463
 in MDS, 436
 HSCT and, 437
 relapse and, 437
MLL and, 172
 neurocognitive, HSCT and, 825
 nutrition at diagnosis and, 660
 in osteonecrosis, 685
 in primary myelofibrosis, 474
 in treatment-related leukemias, 751–753
 parental functioning and, 832, 843, 845
 prediction, gene expression profiling and, 38
 after relapse, 9
 traumatic lumbar puncture and, 338

Index

- ovarian function
 ALL treatment and, 706
 transplant and, 706
- oxazaphosphorines, 320–321
- oxygen steal, hyperleukocytosis and, 674
- p14/15/16 proteins, actions, 182
- p14^{ARF}* gene, 182, 249
- p15 methylation studies, 240–241
 pediatric, 244
- p16^{INK}* gene, 182, 249
- p19^{ARF}* inactivation, 183
- p210^{BCR-ABL}*, *see* BCR–ABL1
- P2RY8-CRLF2* fusion, 174
- p53
 degradation, NPM and, 222
 -induced apoptosis, 385
 in MDS, 434
 ribosomal biogenesis and, 291
 role in ALL, 370
 stability, PML and, 215
 vinca alkaloids and, 264
- p57 methylation studies, 240–241
 pediatric, 244
- p73 methylation studies, 241, 240–241
 pediatric, 244
- packed red cell transfusions, 794–796
- pain management, 814–819, 845
 principles, 814
 procedural, 828–829
- palliation and bereavement
 phases of care, 843, 847–848
- pancreatitis, 662, 682
- panobinostat, 620, 625
- paracetamol *see* acetaminophen
- parental
 cigarette smoking and
 childhood leukemia, 56
 coping, 832
 in relapse, 847
 distress, 845
 education, 841
 in developing countries, 552
 exposure to chemicals, 54, 56
 post-traumatic stress, 831
 tobacco smoking and
 childhood leukemia, 55
- partial tandem duplications (PTD), 214
- partial uniparental disomy, 136
- pathogenesis
 of AML, 397
 of mastocytosis, 477
 of pain, 814
 of polycythemia vera, 464
 primary myelofibrosis, 472
- pathology of Burkitt lymphoma/
 leukemia, 383–385
 molecular, 385
- pathophysiology
 of ALL, 332–334
 CNS leukemia, 676
 of leukostasis, 673, 674
 of MDS, 433
 neuropsychosocial
 impairment, 826–827
 tumor lysis syndrome, 664
- patulin, 8
- PAX5* gene
 in ALL, 181
 in precursor B-ALL, 332
 in progenitor B-ALL, 180
 fusions, 138, 141
 in B-ALL, 177
- PAX5*, roles, 178
- PBX1 complexes, roles, 171
- PBX1*, 171
- PCR *see* polymerase chain
 reaction
- PEBP* genes in FPD/AML, 294
- Pediatric Oncology Group, 5, 8
- Pediatric Preclinical Testing
 Program, 616
- pegfilgrastim, 807
- pentamidine isethionate, 7
- pericarditis–myocarditis
 syndrome
 anthracyclines-induced, 316
- Periodic acid–Schiff (PAS) stain,
 24
- peripheral blast cell count, in
 relapsed ALL, 369
- peripheral blood stem cells,
 530–531, 605
 harvesting, 532
- personnel
 in Brazil, 553
 in developing countries, 552,
 554, 555
- pesticides, parental exposure, 54,
 56
- PETHEMA protocols, Spain, 239
- P-glycoprotein
 cellular drug resistance and,
 259, 268, 423
 inhibitors, 620, 627
 therapeutic use, 604
- Ph *see* Philadelphia chromosome
- pharmacodynamics
 in AML treatment, 408
 definition, 309
 of anti-leukemic therapies,
 309–321
 phase I trials assess, 618
- pharmacogenetics
 of anti-leukemic therapies,
 309–321
 definition, 309
- pharmacogenomics
 in AML treatment, 408
 definition, 309
- pharmacokinetics
 in AML, 410
 of anti-leukemic therapies,
 309–321
 definition, 309
 phase I trials assess, 618
- phases of care
 bereavement,
 diagnosis and referral,
 palliation and bereavement,
 prediagnosis,
 recurrent disease,
 rehabilitation and treatment,
 survivorship,
see also supportive care;
 supportive care needs
 framework
- PHF6* gene, 184
- Philadelphia chromosome (Ph),
 140
 biphenotypic leukemia, 36
 in CML, 248
 diagnosis of CML, 38
 identification of, 11
 -positive ALL, 31, 336, 353
 relapse in, 369
 therapy in, 3
 -positive CML, 460
 in T-ALL, 147
 t(8;14)(q11.2;q32) and, 146
see also BCR–ABL1
- phlebotomy, in polycythemia
 vera, 467
- physical examination, in ALL,
 334
- PICALM-MLLT10* fusion, 177
- Pinkel, D, 12
 St. Jude Children's Research
 Hospital, 8
- Pizzo, PA, antibiotic and
 antifungal use, 6
- plasma concentrations of
 methotrexate, 310
 toxicity and, 310
- plasmablasts, 77
- platelet count
 bleeding risk and, 6, 796
 increment, 798
 platelet transfusion and, 798
- platelet disorder, familial *see*
 familial platelet disorder
- platelet-lowering therapy, 471
- platelet transfusions, 6, 673,
 796–799
 evaluating response to, 799
 in thrombosis, 678
- platinum analogues, 726, 727
- plerixafor, 620, 627
- ploidy, 340
 definition, 137
- PLZF protein, 217
- PLZF–RAR α fusion protein, 217
- PML
 arsenic and, 217
 roles, 215
- PML* gene, 215
- PML-RARA* fusion, 10, 33, 89,
 152, 215–217
 in APL, 402
- PML-RAR α* fusion protein, 215,
 216, 217
- Pneumocystis jiroveci*
 pneumonia, 7, 9, 775
 in chronic GVHD, 540
 prophylaxis, 345, 711, 785
- pneumonia, 775
 syndrome, idiopathic, 538
- political inequality, patterns of,
 550–552
- polycythemia vera, 463–468
 WHO diagnostic criteria for,
 464
- polyglobulia, secondary, 466
- polymerase chain reaction
 (PCR), 9, 632–633
 B-ALL, 124
 for detection of relapse in
 ALL, 368
IG/TCR gene rearrangements,
 117, 119, 120–122, 120–122,
 127
 diagnostic clonality studies,
 126–128
 limitations, 121
 sensitivity, 128
 in MRD monitoring, 410, 636,
 637, 638, 632–638, 644,
 642–645, 647–648
MLL and, 153, 154
 molecular targets, 633
 procedures, 120
 quantitative, 2

- real-time quantitative, 633, 637
 TaqMan, 637, **638**, **644**
 reverse transcriptase, 633
 identifies chromosomal changes, 2
 in AML, 151, 152
 pediatric ALL, 30
 role in diagnosis of ALL, 185
- polymorphisms
 ALL and, 333
 and response to therapy, 408
GCR genes, 260
 inherited, susceptibility to ALL and, 185
 linked to development of leukemia, 3, 731, 732–734
 linked to drug effects, 3
 receptor, methotrexate toxicity and, 311
 susceptibility to malignancy and, 397
 treatment response and, 321
see also single nucleotide polymorphisms
- ponatinib, 620
- population mixing, and childhood leukemias, 57
- posaconazole, 786
- postinduction intensification, 9
- posterior reversible encephalopathy, 684
- postremission chemotherapy, 371–372
- post-traumatic stress, 831–832
- potassium
 hyperkalemia, 666, 667
 hyperleukocytosis and, 674
- poverty
 access to care and, 555
 diseases of, 550
 by country, 551
 under-5 mortality rate and, 550
 treatment abandoned due to, 554
- power lines, electromagnetic fields, 54
- PRAME, 250, 634
- pre-ALL syndrome, 99
- pre-B-ALL
 immunophenotype, 85, 86
 late transitional, 86
- pre-B-cell receptor, 75, 75, 76
- pre-B-leukemia, clinical features, 338
- precursor B-ALL, 28, 29, 84–87
 cellular drug resistance in, 258, 263
 chromosomal abnormalities, 145
CRLF2 in, 332
E2A-PBX1 fusion transcript, 30
 expression profile, 82
 FISH, **139**
 gene rearrangements, 124
 in adolescents, 523
 PCR analysis of junctional regions, 635
 polymorphisms and, 60
 with *BCR-ABL1*, 31
 with genetic abnormalities, 30–32
 with hyperdiploidy, 30
 with hypodiploidy, 32
 with *MLL* rearrangements, 31
 with *TEL-AML1*, 30
- precursor B-cell neoplasms, 385
- precursor natural killer leukemia, 87
 immunophenotype, 87
- precursor T-ALL, 29
 chromosomal abnormalities, 32
 diagnosis, 83
 expression profiles, 83
 polymorphisms and, 60
- prediagnosis phase of care, 840, 843
- predisposition
 to AML, 397
 cancer, 276–278
 hematologic malignancies, 276–298
 heritable, 277
 leukemia, 298
 syndromes in leukemia, 278
see also susceptibility
- prednisolone
 adrenal insufficiency and, 687
 dose, 319
 resistance to, 258
 prognosis and, 257
- prednisone, 8
 in AML, 10
 early use, 4
 in reinduction therapy in relapsed ALL, 370
 in remission induction therapy in ALL, 348
 osteonecrosis and, 685
 pharmacodynamics, kinetics, and genetics, 319–320
- pre-existing conditions, 663
- pregnancy in survivors, 706
- preleukemic myeloproliferative disorder (MPD), chromosomal abnormalities, 150
- preleukemic phase
 treatment-related leukemias, 749
- preleukemic syndrome, 99
- prenatal leukemogenesis, 509, 645
- pre-T-cell receptor (pre-TCR), 78
 β receptors, 77
- prevalence of neurofibromatosis type 1, 286
- prevention of infection, 784–786
- primary cytogenetic lesions, 135
- primary myelofibrosis, 471–475
 WHO diagnostic criteria for, 472
- pro-B-ALL
 flow cytometry, 81
 genetic abnormalities, 85
 immunophenotype, 85, 84–86
- probes, in FISH, 136
- procedures, pain management for, 819, 828–829
- prognosis
 ALL subtypes, 341
 in Burkitt lymphoma/leukemia, 390
 cellular drug resistance and, 257
 MDS, 435–436
 refractory AML, 422
 in relapsed AML, 421
 response to treatment and, 2
 translocation and, 9
- prognostic factors
 drug plasma concentration as, 310
 for neurologic sequelae, 706
 in ALL, 342–344, 525, 643
 in AML, 408–410, 649
 in APL, 410, 648
 in Burkitt lymphoma/leukemia, 389
 in CML, 461, 463
 in DS AML, 510
 in essential thrombocythemia, 470
 infant ALL, 353
 in JMML, 455–456
 in MDS, 436
 MRD as, 3, 410, 642, 643, 647, 649
 in pancreatitis, 682
 in primary myelofibrosis, 474
 in relapsed ALL, 369, 367–370
 in relapsed AML, 422
 in TMD, 507
- progression
 of AML, 435
 of essential thrombocythemia, 470
 of MDS, 435, 435–436
- progressive multifocal leukoencephalopathy (PML), 779
- promonocytes in AML, 34
- promyelocytes
 abnormal, in APL, 23
 characteristics, 23
 hypergranular, 33
 leukemic, 402
- prophylaxis, 785–786
 after HSCT, 537
 antibiotic in AML, 411
 CNS leukemia, 682
 CNS, in Burkitt lymphoma/leukemia, 389
 GVHD, 538, 540
 in MDS, 437
 for neutropenia, CSFs as, 805–807
 platelet transfusions, 798
 thrombosis, 679
- propofol, 819, 829
- proteasome inhibitors, 620, 626
- protein tyrosine phosphatase PTPN11 (SHP-2), 454
PTPN11 gene, 205, 289, 454
- protocol II, 9
- protocols
 experimental, 4
 gene therapy, 607
PRV1 gene, 464
 pseudodiploidy, 30
 in ALL, 137
Pseudomonas aeruginosa, 6, 774, 777
Pseudomonas exotoxin A, 566
 pseudo-Pelger–Huët change, 38
- psychologic interventions
 for pain and distress, 829
 for parents, 832
- psychologic adjustment, 830
- psychosocial issues, 7, 9, 823–833
- psychosocial support, in Brazil, 553
- puberty
 effects of therapy on, 702
 radiation therapy and, 706
- public health
 priorities in developing countries, 550, 555
 system, changes in, and pediatric cancer unit, 556
 pulmonary infections, 775–776

Index

- prophylaxis (*cont.*)
 pulmonary leukostasis, 675
 pulmonary sequelae of therapy, 708
 pure erythroid leukemia, 91
 immunophenotyping, 91
 purine analogues, 423
 in JMML, 457
 pyrimidine analogues, 10
- RAD001, 475
- RAD51* gene, 731
- radiation
 in therapy-related AML, 36
 injury to hypothalamic–pituitary axis, 701, 709
 natural background, 53
 paternal exposure, preconceptually, 53
 testicular, 705
 X-rays
 in utero, 53
 postnatal, 53
- radiation therapy
 and puberty, 706
 CNS tumors and, 712
 dentofacial effects, 708
 for intracerebral myeloid tumors, 677
 in primary myelofibrosis, 474
 neurologic sequelae, 706–707, 823–824
 pathophysiology, 826
 treatment-related cancers after, 728
- radiograph *see* X-rays
- radioisotope–MoAb conjugates, 566
- radiotherapy
 early use, 3
 risk of leukemia after, 53
- radon exposure, 54
- RAF kinases, 458
- RAGs, 114
- randomized phase II trial, 618
- rapamycin, 620, 626
- Rapid Access to Intervention Development (RAID), 617
- retinoic acid receptor α (RAR α)
 in APL, 152–153, 215
 gene *RARA*, 205, 215
- RAS genes, 205, 224, 286
 in AML, 152, 425
 in JMML, 452–453
KRAS, 452
NRAS mutations in AML, 209
NRAS mutations in in JMML, 452
- RAS pathway activation, 289, 450
- RAS proteins, 224, 287, 450
 therapy targeted at, 458
- RAS-associated autoimmune lymphoproliferative diseases, 452
- rasburicase, 388, 667
- RAS–MAPK pathway, 286, 287, 450
 in JMML, 451–453
 therapy targeting, 458
- RASopathies, 286, 450
- RB1* gene, 276
- RBM15 protein, 220, 221
- RBM15-MKL1* fusion, 92, 154, 220
 -mediated leukemogenesis, 221
- reactive thrombocytosis, 470
- receptors, polymorphisms in
 corticosteroid resistance and, 320
 methotrexate toxicity and, 311
- recombinase, 114
- recombinase-activating genes, 114
- recombination signal sequences, 114
- reconsolidation therapy, 9
- recovery, maximizing chance of, 5
- recurrent disease phase of care, 843, 846
- red blood cells
 in JMML, 448
 preservation of, 5
 transfusions, 794–796
 in Diamond–Blackfan anemia, 291
- reduced-intensity conditioning, 280, 532
 second, 535, 537
- refractory anemia, 430
 with excess of blasts, 429, 430, 435
 with ringed sideroblasts, 429
- refractory cytopenia, 435
 of childhood, 38, 430
- refractory leukemia, 11
 clonal evolution and, 3
- rehabilitation, treatment and, phases of care, 840–846
- reinduction therapy, 9
 in ALL, 349–350, 522
 in AML, 423
- in bone marrow relapse, 370–376
 in Burkitt lymphoma/leukemia, 390
- relapse
 in ALL, 367
 diagnosis of, 367, 643
 HSCT in, 374–375
 MRD monitoring in, 643
 prognostic factors, 367–370, 642, 645
 treatment, 371, 370–376
 in AML, 422, 421–425
 MRD monitoring in, 648
 in APL, 424, 648
 bone marrow, reinduction therapy in, 370–376
 in Burkitt lymphoma/leukemia, 390
 category, event-free survival and, 369
 of CML, 463
 clonal evolution and, 3, 184, 185, 636
 CNS, 9, 350
 in ALL, 372–373
 in Burkitt lymphoma/leukemia, 390
 myelopathy in, 684
 combination therapy in, 315
 epigenetics of, 240
 estimated risk, 9
 genetics of, in ALL, 185
 in JMML, 459, 460
 in MDS, 437
 methotrexate plasma concentration and, 310
 outcomes after, 9
 re-accumulation of blasts at, 3
 recurrent disease phase of care, 846
 risk of
 in ALL, 342, 643
 in AML, 410, 648
 in APL, 648
 HSCT and, 533–535
 in JMML, 459
 in MDS, 437
 methotrexate systemic exposure and, 310
 methylation studies of, 240
 myeloablative therapy and, 532
 therapy based on in AML, 204
 testicular, in ALL, 373
 time to, definition, 368
 vs. secondary malignancy, *IG/TCR* clonality studies, 127
- relationships, family–staff, 840
- remission, 5
 in AML, 10
 complete, in ALL, 349
 early experience, 8
- induction, 9
 rate, 5
 treatment, initial response to, 2
 induction therapy, 840
 in ALL, 345, 645: initial response to, 643
 in AML, 404–406
 infection related to, 349
 initial response to, 343
 in MDS, 436, 437
 side effects, 349
 rates in APL, 215
- renal failure, 669
- renal impairment, 669
 from hyperuricosuria, 6
 in Burkitt lymphoma/leukemia, 389
 infection, 779
 pre-existing, 663
 tumor lysis syndrome and, 664–670
- resistance to MoAb-based agents, 574
- resolution, spontaneous, in JMML, 455
- resources, scarce national, limit treatment, 553, 554
- response
 bone marrow, 9
 early rapid, 9
 early vs. late in ALL, 523
 evaluation, 3, 9
- retinoblastoma, epidemiology, 276
- retinoic acid, 10, 457
see all-*trans*-retinoic acid,
- retroviral vectors, 593, 594, 595
- Revised European–American Lymphoma (REAL) classification, 384
- RFC1* polymorphisms, 58
- rhinosinusitis, 776
- ribonucleotide reductase inhibitor, 11
- ribosome biogenesis
 abnormal, 289
 Diamond–Blackfan anemia, 290–291
 dyskeratosis congenita, 292–294
 Shwachman–Diamond syndrome, 291–292
 genetic mutations in, 290
- ribozymes, 598
- ricin–MoAb conjugate, 564, 565, 568

- risk
- assignment in AML, 649
 - classification
 - ALL, 344
 - AML, 408, 410, 410
 - directed therapy in ALL, 332, 345
 - factors, 52
 - for AML, 396–397
 - for Burkitt lymphoma/leukemia, 385
 - for chronic GVHD, 540
 - congenital, 52
 - disease, for early complications, 660
 - environmental, 52–54, 61
 - genetic, 51
 - for hyperglycemia, 686, 687
 - for infection, 772
 - leukemia, for early complications, 663
 - for leukostasis, 673
 - lifestyle, 54–55
 - for myelopathy, 684
 - for neurocognitive impairment, 824
 - for pancreatitis, 682
 - for early complications, 660–663
 - reducing, for treatment-related cancers, 729
 - studies of, 49, 51
 - for thrombosis in essential thrombocythemia, 470
 - for thrombotic complications, 677
 - for traumatic lumbar puncture, 338
 - treatment, for early complications, 660, 663
 - for treatment failure in CML, 463
 - for treatment-related cancers, 725, 727
 - for tumor lysis syndrome, 668
 - for typhlitis, 681
 - groups
 - in ALL, 342–344, 345
 - in relapsed ALL, 369, 369, 370
 - of ALL, 185
 - of donation, 532
 - of leukemia
 - Down syndrome and, 151, 503
 - TMD and, 151
 - of MDS, 431
 - of relapse
 - in ALL, 643
 - in AML, 410, 648
 - in APL, 648
 - CNS, 350
 - estimated, 9
 - HSCT and, 533–535
 - in JMML, 459
 - in MDS, 437
 - myeloablative therapy and, 532
 - therapy based on, in AML, 204
 - of second malignancy, 711
 - growth hormone therapy and, 704
 - of thrombosis, 678
 - of treatment-related cancers, 724–725, 726
 - after chemotherapy, 727
 - after HSCT, 729
 - after radiation therapy, 728
 - genetic variation and, 734
 - of tumor lysis syndrome, 664, 667
 - stratification
 - in ALL, 369, 525, 643
 - groups, 369
 - protocols, in childhood ALL, 185
 - risk-based therapy in essential thrombocythemia, 471
 - rituximab, 390, 563, 564, 568–569, 620
 - side effects, 573
 - Robertson, OH, preservation of red blood cells, 5
 - Romanowsky stain, 24
 - in AML, 26
 - bone marrow, 22
 - romidepsin, 620, 625
 - Rous, P, preservation of RBCs, 5
 - Rowley, JD, Philadelphia chromosome, 11
 - RT-PCR *see* polymerase chain reaction
 - RUNX* genes, 206
 - in AMKL-DS, 219
 - in FPD/AML, 295
 - leukemia predisposition and, 294
 - rearrangements, 208–210
 - in AML, 206
 - in CML, 209
 - see also* AML genes, CBF genes
 - RUNX* proteins, 206–208
 - in FPD/AML, 295
 - RUNX1*
 - in AML, 397
 - iAMP21 and, 175
 - translocation, 741
 - RUNX1*–*CBF β* complex, 207
 - RUNX1*–*ETO* fusion protein, 208–209
 - RUNX1*–*RUNX1T1* fusion, 34, 207–209, 648
 - RUNX1*–*RUNX1T1* expression
 - in AML with t(8;21), 400
 - safety of drugs
 - new guidance, 619
 - phase I trials assess, 618
 - sarcoma, myelocytic or monocytic, diagnosis, 80
 - SBDS* gene, 292
 - SBDS* protein, actions, 292
 - Shwachman syndrome, 51
 - Shwachman–Diamond syndrome, 291–292
 - heritable predisposition, 277
 - MDS and, 38
 - screening, donor, for transfusions, 800, 801
 - secondary chromosomal aberrations, 135
 - secondary malignancy, 711–713, 723
 - IG/TCR* clonality studies to distinguish from relapse, 127
 - treatment-related, 723–755
 - sedation, procedural, 819, 829
 - seizures, 661, 682
 - Sellafield (UK), 53
 - sensitivity
 - of MRD assay by flow cytometry, 640
 - of MRD PCR analysis, 637, 637–638, 647
 - serum response factor, 220
 - severe congenital neutropenia, 296–298
 - heritable predisposition, 277
 - myeloid neoplasia and, 431
 - risk of MDS and, 431
 - sexual development, after therapy, 702
 - shelterin, 293
 - SHMT1* polymorphisms, 58
 - SHP-2* *see* protein tyrosine phosphatase PTPN11
 - Shwachman–Diamond syndrome
 - MDS in, 431
 - myeloid neoplasia and, 431
 - sibling
 - adaptation, 832
 - donor transplants, 11, 374, 406, 530
 - HLA-compatible, 7, 374
 - side effects
 - anticipating, 841
 - drug compliance and, 845
 - in continuation therapy
 - in ALL, 352
 - of G-CSF, 806
 - of methadone, 817
 - of MoAb-based agents, 573–574
 - nausea and vomiting, 829–830
 - neurocognitive deficits, 823–827
 - off-target, in immunotherapy, 584, 603
 - of opioids, 818
 - red cell transfusion, 796
 - remission induction therapy, 349
 - in survivors, 701–713
 - of treatment for ALL, 524–525
 - signal transduction inhibitors in AML, 425
 - signaling pathways
 - in JMML, 450
 - inhibitors, 412
 - SIL-TAL1* fusion, 146, 176
 - single nucleotide polymorphisms (SNPs), 38
 - ALL and, 60
 - arrays for classification of ALL, 39
 - candidate gene studies, 58–59
 - childhood leukemia and genome-wide association studies, 59–61
 - corticosteroid resistance and, 320
 - definition, 136
 - genotyping microarrays, 177
 - in folate metabolism pathway, 58, 311
 - in interleukin-15, 321
 - and methotrexate toxicity, 311
 - and predisposition to leukemia, 53, 735
 - in thiopurine methyltransferase, 311
 - in xenobiotic metabolism pathway, 58
 - treatment response and, 321
 - see also* polymorphisms,
 - single-strand conformation polymorphism analysis, 121
 - skeletal abnormalities after therapy, 709–710
 - skin lesions
 - in chronic GVHD, 540
 - infections, 772, 774–775
 - in JMML, 446
 - rash, antimetabolites and, 352, 352
 - Skipper, HE, multiagent therapy, 8

Index

- small cell tumors, differentiating, 81
- SmIg gene rearrangements, 124
- SmIg-CD79, 117
- SNP *see* single nucleotide polymorphisms
- societal attitudes
 treatment of pediatric cancer and, 550, 555
 twinning programs and, 555
- socioeconomic
 change, and pediatric cancer unit, 556
 inequality, patterns of, 550–552
- soft tissue infections, 774–775
- solvents, parental exposure to, 54
- Soni, SS, neuropsychologic consequences of treatment, 8
- sorafenib, 620, 625
- Southern blot
 analysis of *IGH* genes, 119
 in precursor B-ALL, 127
 B-ALL, 124
IG/TCR gene rearrangements, 119–120
 diagnostic clonality studies, 126–128
 procedures, 119
- Southwest Oncology Group, 5
- spinal cord compression, 676
- spinal lipomatosis, 661, 684
- spleen in ALL, 334
- splenectomy
 in JMML, 458
 in polycythemia vera, 468
 in primary myelofibrosis, 474
- splénomegaly
 in JMML, 446
 in polycythemia vera, 467
 in primary myelofibrosis, 473
- Src kinase dephosphorylation, 81
- St. Jude Total Therapy Study XV, 342
- St. Jude Children's Research Hospital, 8
 diagnostic criteria, 92
 genome-wide association studies, 60
 International Outreach Program, 555
 results for ALL, 556–557
 results for AML, 557–559
 results for Burkitt leukemia/lymphoma, 557–559
 “St. Jude pneumonia”, 7
- Total Therapy studies, 337
- Total-XS protocol, 310
- staff, in developing countries, 552, 554, 555
- staging, Burkitt lymphoma/leukemia, 387
- staining
 bone marrow, 22
 histochemical, introduction of, 2
- staphylococcal infection, 6
 catheter-related, 773
- Staphylococcus aureus*, 6, 774
- statistical power of trials, 5
- stem cell factor, 605
- stem cell transplantation *see* hematopoietic stem cell transplantation
- stem cells, 7
 gene marking in, 605
 sources, 530, 531
- Streptococcus* spp., 774
- Streptococcus viridans*
 in AML, 411
 prophylaxis, 785
- stressors, family, during treatment, 845
- Subbarow, Y, antifolates, 4
- subclones, 2
 formation, 127
 at diagnosis, 124
IG/TCR clonality studies, 126, 127
- subgroups
 AML, 400–404
 MDS, 429
- submicroscopic molecular genetics, 136
 future trends, 158
 in ALL, 173
 in AML, 204
 in B-ALL, 182
 in T-ALL, 182–184
- sub-Saharan Africa, Burkitt lymphoma/leukemia in, 558
- subtype-specific treatment, of APL, 412
- Sudan Black B stain, 24, 24, 29
 applications, 27
- suicide genes, 589, 604
- sulfamethoxazole, 7
- sunitinib, 620
- superinfection, 6
- superior mediastinal syndrome, 337
- superior vena cava syndrome, 337, 661, 671, 671, 672
- support
 blood component, 794–800
 for family in Brazil, 553
 patient, in Brazil, 553
 venous access, 802–803
- supportive care, 5–8
 in ALL, 344–345, 349
 in AML, 411
 in Brazil, 553
 definition, 839
 in developing countries, outcome and, 554, 556–558
 hematologic, 794–809
 in hyperleukocytosis, 675
 mucositis and, 681
 in myelopathy, 685
 supportive care needs framework, 839, 839–848
 survival due to, 660
 in tumor lysis syndrome, 667
- supportive care needs framework, 839, 839–848
- suppressor of cytokine signaling proteins in CML, 249
- Surveillance, Epidemiology, and End-Results (SEER) program (US), 50
- survival
 in ALL
 adolescents, 523
 age at diagnosis and, 520, 523
 cancer treatment in Brazil assessed by, 552
 in ALL-DS, 505
 in AML, 395, 396
 bone marrow transplantation and, in AML, 536
 early therapies, 8
 in essential thrombocythemia, 470
 HSCT and
 in ALL, 533–535
 in AML, 424, 535–536
 mismatched donor, in JMML, 456, 457
 HSCT and, 456
 in MDS, 436, 436
 HSCT and, 437
 pediatric cancer, wealth and, 551
 in polycythemia vera, 467
 postrelapse in AML, 422
 in primary myelofibrosis, 474
 quality, 8
 rates
 in AML, 10, 408
 in CML, 12
 remission and, 5
- in treatment-related leukemias, 751–753
- survivin, 435
 antagonists, 620, 627
- survivors
 concerns in, 846
 psychosocial issues for, 823
- survivorship phase of care, 843, 846
- susceptibility
 alleles, leukemia risk and, 298
 to cancer, genetic variation and, 732
 drug metabolism and, 397, 735
 genetic, 58–61
 environmental risks and, 61
see also predisposition
- syndrome of inappropriate secretion of antidiuretic hormone (SIADH), 661, 686
- systemic exposure, risk of relapse and, with methotrexate, 310
- systemic inflammatory response syndrome in AML, 411
- systemic mastocytosis, 477
- T-ALL *see* T-cell acute lymphoblastic leukemia
- T-cell acute lymphoblastic leukemia (T-ALL), 9, 122
 cellular drug resistance in, 258
 chromosomal abnormalities, 146–147
 chromosomal rearrangements, 176–177
 classification, 87
 immunologic, 87
 compared to B-cell precursor ALL, 339
 flow cytometry, 81
 gene rearrangements, 124, 125
 aberrant and oncogenic, 125
 genetic subgroups, 342
IG/TCR genes
 PCR analysis of junctional regions, 635
 rearrangements, 124, 127
 immunophenotype, 87, 87
 outcomes, 146
 Ph⁺, 147
 treatment, 354
- T-cell leukemia
 clinical features, 339
 immature thymocyte, 339
 mature thymocyte, 339
 prothymocyte, 339
- T-cell lymphoblastic lymphomas, 122
 gene rearrangements, 124

- T-cell neoplasms, aberrant *TCR* rearrangements in, 125
- T-cell receptor excision circle (TREC), 115
- T-cell receptor (TCR), 78
 antigen specificity, 113, 603
 encoding genes, 113
 gene transfer, 603
 immunoglobulins on, 113
 molecular structure, 113
- T-cell receptor gene *see TCR* genes
- T-cells
 activation, 583
 chimeric antigen receptors specificity, 602
 CD4⁺/CD8⁺, 582
 in graft-versus-leukemia effect, 585
 depletion, 531, 533, 537, 539, 586
 gene marking, 606
 immunotherapy, 584, 584–587
 lineage
 expression profile, 83
 maturation and differentiation, 78
 maturation, 77
 modification by gene therapy, 601–604
 suppression, overcoming, 589
 Th1/Th2 and Tc1/Tc2 subsets, 585
- T-lineage lymphoid malignancies
 incidence and distribution, 124
- TAL genes
 expression profiling, 39
 in precursor T-ALL, 32
 in T-ALL, 125, 146, 176
- TAL1
 actions, 176
 overproduction, 126, 176
- TAL1-E2A, actions, 176
- TALE proteins, 171, 213
- tandem duplication, *MLL*, 214
- TCF3-HLF* fusion, 186
 in B-ALL, 172
- TCF3-HLF*, actions, 172
- TCF3-PBX1* fusion, 333
- TCF3-PBX1*, actions, 172
- TCL1* gene, 282
- TCR *see* T-cell receptor
- TCR* genes, 88, 114
 complexes, 114
 expression, 77
- rearrangements, 115, 115, 116, 118, 145
 aberrant, 125
 cross-lineage, 123, 125
 diagnostic studies, 127
 during lymphoid differentiation, 116–119
 in precursor B-ALL, 123
 junctional regions in PCR analysis, 635, 637, 634–638
 oncogenic, 125
 PCR analysis, 120
 secondary, 116
 in T-ALL, 125, 146, 176
 in T-ALL and T-LBL subgroups, 125
 transcription factors and, 126
- TCR molecules
 combinatorial diversity, 115
 junctional diversity, 116
 repertoire, 115, 115–116
- TdT *see* terminal deoxynucleotidyl transferase
- TEL* gene, 156
 rearrangements, 144, 142–144, 157
 in AML, 148
- TEL-AML1* fusion, 51, 143
 in ALL, 30
 and relapse, 370
 cellular drug resistance and, 263
- telomerase complex genes, 293
- telomeres, 293
 dyskeratosis congenita and, 432
 length, analysis, 294
 maintenance, dyskeratosis congenita and, 293
- temozolomide, 622
- temperature gradient gel electrophoresis, 121
- temperature, monitoring, 842
- temsirolimus, 375
- teniposide, 265, 317
 drug–drug interactions, 319
 leukemogenicity, 56
 treatment-related leukemia and, 727
- TER* genes, 293, 433
- terminal deoxynucleotidyl transferase (TdT), 77, 84
 in gene rearrangements, 116
- terminology, changes in, epidemiology and, 49
- testicular leukemia, in ALL, 334, 335, 367
- testicular relapse treatment, 373, 705
- TET2* gene, 246, 432
- tetraploidy, 30
- therapeutic index, drug toxicity and, 309
- therapeutic range of teniposide, 317
- therapy
 adjuvant immune, 783–784
 alkylator, in Burkitt leukemia/lymphoma, 3
 in ALL, future trends, 354, 525
 in AML, 204
 CNS-directed, 350–351
 consolidation, in ALL, 522
 continuation, 9, 845
 in ALL, 351–352
 developing new, 620, 616–627
 differentiation, in AML, 424
 in AMKL-DS, 510–513
 early response, 9
 epigenetic, 246–248
 experimental, in primary myelofibrosis, 475
 for pain
 non-pharmacological, 818
 pharmacological, 815–818
 for treatment-related leukemia, potential, 753–755
 gene expression profiling and, 39
 growth hormone, 703
 inadequate, evolution of leukemia after, 11
 -induced leukemias, 606–607
 intensification
 in ALL, 522
 in AML, 406
 MRD detection as criterion, 649
 maintenance, in ALL, 522
 molecularly targeted, 624–627
 multiagent, 8
 myeloablative
 growth after, 703
 in MDS, 436, 437
 reinduction
 in ALL, 522
 -related complications
 in ALL, 524–525
 -related leukemias, 723–755
 AML, 36, 404
 in neurofibromatosis, 287
 -related MDS, 404, 437
 -related myeloid neoplasms, 36, 88
 -related secondary cancers, 278
 remission induction, 840
 in ALL, 345–349, 643, 645
 in AML, 404–406
 infection related to, 349
- initial response to, 343
 in MDS, 437
 side effects, 349
 response to, and outcome, 410, 643
 risk-directed in ALL, 342, 345
 “species-specific”, 9
 supportive care, in ALL, 344–345
 undifferentiated, success of, 3
see also treatment
- thiarabine, 622
- thioguanine, 10, 267, 312
 in AML, 404
 hepatic effects, 710
 metabolism, 312
 nucleotides, 311
 in red blood cells, 311–313
- thiopurine methyltransferase deficiency, 311–313, 663
 polymorphisms of *TPMT*, 3, 267, 311, 733
- thiopurines, 266, 267, 312
 cellular drug resistance, 258, 266
 mechanisms, 267–268
- Thomas, ED, bone marrow transplant, 7
- Three Mile Island reactor accident, 53
- thrombocythemia
 essential, 468–471
 hereditary, 470
- thrombocytopenia, 23
 in ALL, 336, 344
 at diagnosis, 672
 drug-induced, 6
 in JMML, 38, 448
 platelet transfusion in, 796
- thrombocytopenic bleeding, 6
- thrombocytosis, reactive, 470
- thrombolytic therapy, 678
 for occluded catheters, 803
- thrombopoietic growth factors, 807
- thrombopoietin, 809
- thrombosis, 662, 678, 677–679
 as early complication, 672
- thrombotic coagulopathy, 673
- thrombus formation in catheters, 803
- thymus, in ALL, 337
- thyroid cancer, as second cancer, 711
- thyroid function, radiation therapy and, 702

Index

- time to diagnosis of a secondary malignancy, 748
see also latency
- time to relapse
 definition, 368
 event-free survival and in ALL, 368
- tipifarnib, 620, 624
- tissue typing for HSCT, 528–530
- TLX* genes in T-ALL, 146, 147, 176
- T-lymphoblastic leukemia *see* precursor T-ALL
- TMD 29 *see* transient myeloproliferative disorder
- tobacco smoking
 maternal, during pregnancy, 55, 59
 parental, and childhood leukemia, 55, 56
- tolerability, drug, phase I trials assess, 618
- topoisomerase II, 265
 anthracyclines and, 265
 inhibition
 by anthracyclines, 56
 dietary, 56
 inhibitor hypothesis, 56, 57
 poisons and secondary leukemia, 726–728
 and resistance to epipodophyllotoxins, 265
- topoisomerase II inhibitors
 exposure in utero, 333, 739
 therapy-related AML and, 36
- topoisomerase II poisons, 725
 cytogenetic and molecular genetic changes due to, 739–744
 DNA damage mechanisms, 744–747
 -related leukemias, 726
 clinical presentation, 748
- total body irradiation, 532
 cataracts and, 707
 in Fanconi anemia, 280
 growth after, 702
 pregnancy after, 706
- total intravenous anesthesia, 819
- total therapy approach in ALL, 344–353
- toxicities, overlapping, 9
- toxicity
 amphotericin B, 783
 cardiopulmonary, 707–708
 complications from, 660
 cyclophosphamide, 320
 Down syndrome and, 506, 511
 drug resistance and, 423
 drug, phase I trials assess, 618
 endocrine, late, 701–706
 epipodophyllotoxins, 316, 317
 gastrointestinal, 311
 glucocorticoid, 319
 mercaptopurine, 311, 313
 methotrexate, 310
 MoAbs, 573
 profile, phase II trials and, 618
 teniposide, 317
 therapeutic index and, 309
 thiopurines, 312
 vincristine, 320
- toxicology studies of novel agents, 617
- toxin–MoAb conjugates, 565
- toxoplasmosis, cerebral, 778
- TP53* gene, 205, 249, 730, 734, 738
- trachea, compressed, 670, 671
- TRAIL receptors, 573
- training
 in developing countries, 552, 555
see also education
- transcription factors
 in AML, 225
 CEBP, 224
 HLF, 172
 gene rearrangements and, 172
 HOX, 176
 gene rearrangements and, 172
 roles, 171
 in CML, 249
 rearrangement of encoding genes, 168
 in ALL, 168
ETV6, 169
MYC, 174
RUNX1, 169
 in T-ALL, 176
 serum response factor (SRF), 220
TCR genes and, 126
- transcriptional repressors, PLZF protein, 217
- transcriptional targeting, 599
- transcutaneous electrical nerve stimulation, 818
- transforming growth factor- β , 604
- transfusion
 in AML, 411
 associated infections, 800, 800–802
 blood components and indications, 795
 coagulopathy and, 673
 granulocyte, 784
 packed red cells, 794–796
 platelet, 796–799
 evaluating response to, 799
 reactions, 797
 refusal of, erythropoietin in, 807
 therapy, 5–6
 in thrombosis, 678
- transient abnormal myelopoiesis, 88, 93
- transient leukemia *see* transient myeloproliferative disorder
- transient myeloproliferative disorder (TMD), 29, 93, 151
 Down syndrome and, 34, 93–94, 506–508
 in DS AMKL, 218
GATA1 in, 217
 genetic lesions, 220
 progression, 219
- translocation
 11q23, 94
 Burkitt, 122
 definition, 135
 immunophenotype-specific, 145
 t(8;22)(q24), 385
 t(1;11)(q21;q23), 35
 t(1;14)(p32;q11), 176
 t(1;14)(p32;q11.2), 146
 t(1;19), 139–140, 340, 342
 t(1;19)(q23;p13), 30, 171
 t(1;19)(q23;p13.3), 139
 t(1;22), 154, 219–220
 t(1;22)(p13;q13), 92, 94
 t(1;7)(p32;q34), 125
 t(10;11), 154
 t(10;11)(p11.2;q23), 35
 t(10;11)(p12;q14), 156
 t(10;11)(p13;q14), 177
 t(10;11)(p13–15;q14–21), 173
 t(10;14)(q24;q11), 125
 t(11;14)(p13;q11), 125
 t(11;14)(p13;q11.2), 147
 t(11;14)(p15;q11), 125
 t(11;17), 33
 t(11;19)(q23;p13), 154
 t(12;19)(p13.3;p13.3), 140
 t(12;21), 142–144, 340
 t(12;21)(p13;q22), 30, 169
 t(14;21)(q11;q22), 125
 t(15;17), 9, 90, 152–153, 742, 749
 t(15;17)(q22;q21), 10
 t(15;17)(q22;q12), 33
 t(15;17)(q22;q1221), 215
 t(16;16), 742, 749
 t(16;16)(p13.1;q22), 35, 152, 401
 t(16;16)(p13;q22), 90, 206
 t(16;21)(p11.2;q22.3), 157
 t(16;21)(q24;q22), 157
 t(17;19)(q22;p13), 172
 t(17;19)(q22;p13.3), 140
 t(19;19), 140
 t(2;8)(p11;q24), 385
 t(3;21), 155
 t(3;5), 155
 t(4;11), 32, 82
 t(4;11)(q21;q23), 31, 173
 t(5;11), 155
 t(5;14)(q35;q11), 125
 t(5;14)(q35;q32), 125
 t(6;11)(q27;q23), 35
 t(6;14)(p22;q32), 145
 t(6;7)(q23;q32–q36), 125
 t(6;7)(q23;q34), 146
 t(6;9), 155
 t(6;9)(p23;q34), 90
 t(7;10)(q34;q24), 125
 t(7;11)(q34;p13), 125
 t(7;11)(q34;p15), 125
 t(7;12), 156
 t(7;12)(q34;p13), 125
 t(7;19), 176
 t(7;19)(q34;p13), 125
 t(7;19)(q34;p13.2), 147
 t(7;7)(p14;q34), 125
 t(7;9)(q34;q32), 125, 147, 176
 t(7;9)(q34;q34), 125
 t(8;14)(q11.2;q32), 146
 t(8;14)(q24.1;q32), 144–146
 t(8;14)(q24;q11), 125
 t(8;14)(q24;q32), 174, 385
 t(8;16), 742, 749
 t(8;16)(p11.1;p13.3), 155
 t(8;21), 9, 151–152, 208, 741, 749
 t(8;21)(q22;q22), 34
 t(8;21)(q22;q22.3), 206
 t(9;11), 154
 t(9;11)(p21;q23), 35
 t(9;11)(p22;q23), 173
 t(9;14)(p13.2;q32), 145
 t(9;22), 140, 248, 743, 749
 t(9;22)(q34;q11), 11
 t(9;22)(q34;q11), 170
 t(9;22)(q34;q11.2), 31, 37
 t(p13;q22), 51
 t(v;11q23), 31, 37
- translocations
 8q24, 28
 in ALL, 51, 168, 340
 in ALL-DS, 504–505
 in AML-DS, 508
 detection, 30
 immunophenotype and, 2
 in JMML, 448
MLL, 739–741, 745
 in precursor B-ALL, 30
 prognosis according to, 9
RUNX gene, 208
 topoisomerase II poisons and, 739, 746, 749
 in treatment-related leukemia, 739

- transplant-associated microangiopathy, 538
- transposon-based vectors, 597
- traumatic lumbar puncture, 338
- treatment
- of ALL
 - complications, 524–525
 - future trends 354
 - pediatric vs. adult protocols, 521–523, 524
 - of ALL-DS, 506
 - altering, to reduce risk of secondary cancer, 729
 - of AML, 404–411
 - future directions, 411–412
 - of APL, 407–408
 - initial response in APL, 215
 - barriers to, 554–555
 - Burkitt lymphoma/leukemia, 387–390
 - of CML, 461–463
 - developing new, 616–627
 - early attempts, 3
 - efficacy, remission duration as measure of, 5
 - of essential thrombocythemia, 471
 - evaluation, approach, 128
 - failure, methotrexate plasma concentration and, 310
 - of graduated intensity, 554
 - intervention studies, MRD-based, 649
 - in JMML, 456–460
 - of mastocytosis, 479–480
 - novel, 480
 - in MDS, 436–437
 - neuropsychological consequences, 8
 - in polycythemia vera, 467–468
 - of primary myelofibrosis, 474–475
 - experimental, 475
 - principles of, in ALL, 345
 - in relapsed ALL, 371
 - CNS, 372–373
 - testicular, 373
 - of relapsed ALL, 370–376
 - of relapsed AML, 423–425
 - related cancers
 - after chemotherapy, 725–728
 - epidemiology, 724–725
 - after radiation therapy, 728
 - reducing risk of, 729
 - related death, 660
 - related leukemias, 56, 723
 - AML, 404
 - clinical presentation, latency, and diagnosis, 747–750
 - cytogenetics and molecular genetics, 735–744
 - etiology, 744–747
 - management algorithm, 750
 - preleukemic phase, 749
 - treatment of, 750–755
 - related MDS, 404
 - related mortality in myeloablative therapy, 527
 - related toxicity in DS AML, 511
 - remission induction, 840
 - resistance, secondary genetic alterations and, 184
 - response, SNPs and, 321
 - results in ALL, 346
 - of thrombosis, 678
 - in TMD, 507
 - treatment and rehabilitation phases of care, 840–846
 - see also* therapy
- treatment and rehabilitation phases of care, 843
- triazoles, 783, 786
- trimethoprim, 7
- triploidy, 30
- trisomy 21, 219
 - in ALL, 504
 - in AMKL, 508
 - and hematopoiesis, 219
 - and leukemogenesis, 509, 510, 512
 - leukemogenesis in, 218
 - in MDS, 434
 - in TMD, 507
- trisomy 8
 - in MDS, 431
 - in ALL, 340
 - in AMKL, 402
 - in AML, 148, 150
- trisomy, triple, 137
- trisomy X, in ALL-DS, 504
- troxacitabine, 622
- truthfulness, 7
- tumor cells
 - immune system recognition, 582–584
 - modification by gene therapy, 597–601
- tumor correction, 598, 599
- tumor lysis syndrome, 6, 661, 664–666, 669
 - in AML, 411
 - assessment and management algorithm, 668
 - in Burkitt lymphoma/leukemia, 388, 389
- tumor necrosis factor- α in JMML, 449
- tumor suppressor genes inactivation
 - by aberrant DNA methylation, 239
 - in neurofibromatosis, 287, 453
 - in MDS, 432
 - mutations
 - as first hit, 276
 - p53*, in Burkitt lymphoma/leukemia, 385
 - in T-ALL, 183
- tumor suppressors
 - NPM, 221
 - p14/15/16*, 183
- tumor vaccines, 599–600
- tumorigenesis
 - gene therapy-related, 606
 - RAS-induced, 224
- tumors, childhood leukemia risk and, 52
- tumor-specific antigens, 583, 583
- Turner, JR, preservation of RBCs, 5
- twin studies, 52
 - in ALL, 333
 - relapse genetics, 184
- twinning programs, 552, 554, 555–556
 - results of treatment of ALL, 556–557
 - results of treatment of AML, 557–559
 - results of treatment of Burkitt leukemia/lymphoma, 557–559
- two-hit hypothesis, 276, 453
- typhlitis, 662, 681, 777
- tyrosine kinase inhibitors, 9, 11, 12, 171, 620, 624, 754
 - in AML, 425
 - in CML, epigenetics and, 249, 250
 - novel, 375, 462
 - in Ph⁺ ALL, 3
 - second-generation, 12, 624
- tyrosine kinases, 222–224
 - activity
 - of ABL, 170
 - of BCR, 170
 - encoding gene abnormalities, 157–158
 - in CML, 249
- tyrosine phosphatase (SHP-1) in CML, 249
- tyrosine phosphatase (SHP-2), 454
- tyrosine protein kinase inhibitors in CML, 461–463
- ubiquitin-proteasome-dependent pathways, inhibitors, 412
- unconjugated MoAb, 563
- under-five mortality rate, national wealth and, 550
- United Nations International Children's Emergency Fund (UNICEF), 550
- urate oxidase, 6
- uric acid levels, 664, 665, 667
 - in ALL, 337, 344
 - in B-ALL, 388
- uricolytic agents, in B-ALL, 388
- urinary side effects of therapy, 710
- urinary tract infections, 779
- USA, childhood leukemia incidence, 49, 50
- V(D)J*
 - combinatorial diversity, 115
 - exon, 113, 114
 - coupling, 114
 - somatic hypermutations, 116
 - gene rearrangements, 114, 115, 116, 120, 122, 127
 - junctional regions in PCR analysis, 636, 634–638, 644
 - proto-oncogenes and, 126
 - recombination mechanism, 114, 282
- vaccination, 786
 - DNA vaccines, 600–601
 - immunotherapy strategies, 425
 - measles, 7
 - repeating, 711
 - tumor vaccines, 599–600
 - varicella, 7
- valproic acid, 620, 625
- vancomycin, 6, 780, 781
 - in venous catheter, 804
- varicella, 7, 775
 - in chronic GVHD, 540
- varicella zoster virus, 775
- varicella zoster immuno-globulin, 7
- vectors, gene therapy, 593–597, 606
- veliparib, 620, 627
- Velpau, A, first report of leukemia, 1
- vena cava, superior, 671
- venous access support, 802–803
 - devices, nursing care of, 841

Index

- Vernick, J, truthfulness, 7
- vinca alkaloids, 263, 264
 resistance to, 258, 264, 268
 mechanisms, 263–264
- vincristine, 8
 in ALL, 345, 349, 352, 521
 in AML, 10
 cellular drug resistance, 258,
 263–264
 intraindividual variability and,
 320
 new formulations, 620, 621
 pharmacodynamics, kinetics,
 and genetics, 320
 pharmacology, and outcome, 3
 in relapsed ALL, 370
 SIADH and, 686
- viral antigens, 583, 583
- viral infections, 7
 cystitis, 779
 after HSCT, 537
 imitate JMML, 449
 myeloablative therapy and,
 527
 skin, 775
 transfusion-associated, 800
- Virchow, R,
 cellular origin of leukemia, 1
 linked leukemia to white
 blood cells, 1
 “splenic leukemia”, 11
- viridans streptococci
 in AML, 411
 prophylaxis, 785
- virotherapy, 598
- visceral pain, 814
- visilizumab, 564, 567
- vita cuff, 804
- vitamins, maternal use in
 pregnancy, 55
- von Willebrand factor in
 essential thrombocythemia, 469
- voriconazole, 783, 786
- vorinostat, 185, 620, 625
 in combination therapy, 248
 as histone deacetylase
 inhibitor, trials of, 248
- wealth, pediatric cancer survival
 and, 551
- weight
 ALL therapy and, 704–705
 drug dosage and, 660, 662
- West Nile virus, blood
 transfusions and, 802
- WHO *see* World Health
 Organization
- Wilms’ tumor gene (*WT1*)
 in AML, 409
 in PCR assays for MRD, 634
- Wnt/ β -catenin pathway, 266
- wood dust, parental exposure, 54
- World Health Organization
 (WHO)
 classification
 of ALL, 29
 of AMKL, 154
 of AML, 9, 23, 147, 155,
 204, 204, 399, 735:
 algorithms, 33
 of AML subtypes, 35, 88
 of eosinophilic disorders,
 475
 of hematopoietic and
 lymphoid neoplasms, 444
 of hematopoietic
 neoplasms, 32, 429
 of JMML, 445
 of JMML and chronic
 myelomonocytic leukemia,
 38
 of lymphoma, 383, 384
 of mastocytosis, 478
 of MDS, 434
 mixed phenotype
 leukemias, 37
MLL subgroup, 154
 molecular, 30
 of MDS
 of myeloid neoplasms, 444
 of myeloid proliferations,
 151
 of T-ALL, 87
 of t(5;12), 157
 of t(9;11), 154
- criteria
 for essential
 thrombocythemia, 468
 for polycythemia vera, 464
 for primary myelofibrosis,
 472
- guidelines on pain therapy,
 815
- HLA nomenclature, 528
- International Nonproprietary
 Name (WHO-INN)
 committee, 617
- Wright stain, 22
- Wright-Giemsa stain, Burkitt
 lymphoma, 383
- xanthine nephropathy, 665
- xanthine oxidase, allopurinol
 and, 6, 667
- xanthogranulomas, in JMML,
 446
- xenobiotic pathway genetic
 polymorphisms, 58–59
- X-linked lymphoproliferative
 disease
 and risk of Burkitt
 lymphoma/leukemia, 386
- XPD protein, 731
- X-rays
 chest, 776
 findings in ALL, 337
 mediastinal mass, 670, 671
 as early treatment, 3
- XRCC1* gene, 731
- zebularine, 622
- zinc finger nucleases (ZFNs),
 599
- zoledronic acid, 457
- zygomycoses, 774, 783